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General introduction
Acute Kidxney Injury
Acute kidney injury (AKI) represents an abrupt decrease in renal function that leads to 
accumulation of nitrogenous waste products such as blood urea nitrogen and creatinine. 
AKI refers to a complex disorder that comprises multiple causative factors (ischemic, 
nephrotoxic and septic components with overlapping pathofysiological mechanisms) 
and occurs in a variety of settings with numerous clinical manifestations that range from 
minimal elevation in serum creatinine (SCr) to anuric renal failure. In the critical care 
setting, AKI affects 5-25% of patients and accounts for an overall mortality rate of 50-
80% [1]. Once established the treatment of AKI is largely supportive, unsatisfactory and 
associated with a poor prognosis [2]. Furthermore, AKI is independently associated with 
an increased risk of death and with a prolonged length of stay [3]. Even small changes 
in SCr can affect outcome in severely ill patients with multiple-organ dysfunction [4, 
5]. Progressive insight in pathofysiological mechanisms of AKI has shown that tubule 
cell necrosis is rarely encountered in human acute renal failure, indeed the disparity 
between the severe impairment of renal function and the relatively subtle histological 
changes in AKI  have been bothersome.  
Definition of AKI
Over 35 definitions have been used to define AKI in the nephrology literature  [6]. 
This is a result from the well recognized uncertain relationship between “the gold 
standard biomarkers” (serum creatinine and urine output) and the AKI disease process. 
Creatinine is the product of the breakdown of creatine to phosphocreatine in skeletal 
muscle and of the subsequent liver metabolism of creatine to form creatinine. It is 
released into plasma and filtered by the glomerulus. A small amount is also secreted 
into the urine through active transtubular transport. Creatinine is not reabsorbed in the 
tubules or metabolized by the kidney. If filtering of creatinine is deficient, blood levels 
rise with an inverse hyperbolic relationship with GFR (Figure 1). Thus, SCr is not an 
injury marker but rather a reflection of functional glomerular filtration. It is an unreliable 
indicator during acute changes in kidney function for several reasons. First, SCr levels 
can vary widely with age, gender, lean muscle mass, muscle metabolism, and hydration 
status. Second, SCr concentrations may not change until about 50% of kidney function 
has already been lost (Figure 1). Third, tubular excretion, especially at lower rates of 
glomerular filtration, results in an overestimation of renal function.  Finally, during acute 
changes in glomerular filtration SCr does not accurately depict kidney function until 
steady state equilibrium has been reached which may require several days. Still, for 
lack of a better alternative, the Acute Kidney Injury Network (AKIN) introduced the term 
“AKI” based upon relative changes of SCr during their first consensus meeting in 2005.
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RIFLE and AKIN criteria
The acute Dialysis Quality Initiative (ADQI) formulated a consensus definition: the risk, 
injury and failure, loss, end-stage renal disease (RIFLE) classification for AKI [7]. It is 
based upon the relative changes in SCr compared to a steady state baseline value and 
changes in urine output (UP) over time corrected for ideal body weight (Table 1A). Later 
AKIN, an organisation dedicated to the improvement of outcomes for patients with AKI, 
proposed small modifications to the RIFLE system [8]. These modifications are based 
upon the particular inability of SCr to reliably define AKI in the milder forms of the 
disease. The primary change was to include a 0.3 mg/dl (= 27 µmol/l) rise in SCr even 
if it was less than 50% increase from baseline. And a 48 hour window was proposed in 
order for the first criterion to be achieved (staging according would then be based on the 
worst values during hospital stay) (Table 1B). Several limitations must be recognized 
using this consensus definition: First, the introduction of urine output criteria may add 
more confusion since oliguria can be masked by diuretics. Second, the conversion of a 
continuous variable to a dichotomous outcome is a problem: AKI or no-AKI, a cut-off is 
arbitrarily applied. Third, an inherent limitation is the need for a steady state baseline 
SCr value which is often very difficult to establish in emergency medicine. 
Biomarkers
The imperfections of SCr urged the need to discover novel injury markers. Therefore, the 
identification of AKI biomarkers has been designated as a top priority by the American 
Society of Nephrology. Functional genomics and DNA micro array-based technologies 
have provided expression profiles of thousands of upregulated genes in case of AKI. These 
studies have identified novel genes with altered expression and new signal transduction 
pathways. Their protein products appear in plasma and urine and have been proposed 
Figure 1: The physiological relationship between serum creatinine concentration and estimated 
glomerular filtration rate.
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as promising new tools in the detection of (subtle) cellular injury. In general and ideally, 
biomarkers should aid in early diagnosis and prediction but may serve several other 
purposes in AKI. Such as: discerning AKI subtypes (prerenal, intrinsic renal, post renal); 
identifying AKI etiologies (ischemia, toxins, sepsis or a combination); differentiating AKI 
from other forms of kidney disease; predicting AKI severity; monitoring the course of 
AKI; and monitoring the response to AKI interventions. The biomarkers described in this 
thesis can be divided in three major categories: functional markers, upregulated low 
molecular weight proteins and constitutive cytoplasmatic enzymes.
Functional biomarkers
Plasma Cystatin-C
Cystatin-C (CyC) is a 13 kDa cysteine protease inhibitor that is synthesized and released 
into the blood at a relatively constant rate by all nucleated human cells. It is freely 
filtered by the glomerulus and under normal conditions completely reabsorbed in the 
proximal tubule. Furthermore there is no evident transtubular secretion. Although it 
is generally considered less subject to the non-renal variables that impact creatinine, 
some studies suggest that levels may be affected by various measures, as well as 
inflammatory processes, use of corticosteroids and changes in thyroid function [9-11]. 
With a half-life of 2 hrs, plasma CyC reflects glomerular filtration better than SCr in 
patients with chronic kidney disease [12]. 
Upregulated low molecular weight proteins
Neutrophil Gelatinase-associated Lipocalin
Neutrophil gelatinase-associated lipocalin (NGAL) is a small (35 kDa) iron trafficking 
protein that is produced by epithelial cells throughout the human body (kidney, 
lungs, stomach, and colon) and is furthermore present in specific granulae of human 
neutrophils [13]. In healthy nephrons it can be detected in the distal tubular epithelial 
cells and the collecting ducts in small amounts, where it is believed to play a role in 
bacterial defense mechanisms. In case of AKI, NGAL mitigates iron-mediated toxicity by 
providing a reservoir for excess iron and may provide a regulated source of intracellular 
iron to promote regeneration and repair. Besides the transportation of iron, NGAL plays a 
critical role in kidney development during conversion of kidney progenitors into epithelia 
and tubules. Administration of NGAL in experimental models before, during or shortly 
after ischemic injury provides protection at the functional and structural levels with an 
induction of proliferation and inhibition of apoptosis of tubule epithelial cells [14-17]. In 
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AKI, plasma NGAL is easily filtered and undergoes a megalin-cubulin mediated re-uptake 
process in the proximal tubular cells where NGAL is degraded in specific lysosomes [18]. 
In distal tubular injury NGAL is generated in large amounts which can be detected in 
the urine [19].  However, urinary NGAL excretion is proportional to albumin excretion 
in mouse models of diabetic nephropathy and is thus augmented when the proximal 
transport maximum is exceeded [15, 19, 20]. NGAL measurements may be influenced 
by a number of coexisting variables such as preexisting renal disease and systemic or 
urinary tract infections [21].  
Kidney injury molecule -1
Kidney injury molecule-1 (KIM-1) is a type-1 transmembrane glycoprotein localized 
to the apical membrane of exclusively surviving proximal tubular epithelial cells after 
injury. In normal renal tissue and normal urine it is not detectable (<0.1 ng/ml)[22]. 
KIM-1 expressing epithelial cells phagocytose intra luminal apoptotic and necrotic cell 
debris and the KIM-1 ectodomain is shed into the urine [23, 24]. Therefore it has been 
proposed as a site specific marker in AKI.  
Constitutive cytoplasmatic enzymes
Glutathione-S-transferase
Alpha-glutathione-S-transferase (α-GST) and pi-GST (π-GST) are constitutive 
cytoplasmatic enzymes belonging to a large family of molecules participating in the 
defense against oxidative stress. The GST enzymes are present in many tissues in the 
human body and are involved in detoxification of foreign compounds by the addition of 
glutathione to a wide variety of xenobiotics. In the kidney, α-GST is localized exclusively 
in the proximal tubular cells, whereas π-GST is detectable in distal tubular cells and 
glomerular podocytes in Bowman’s capsule. Although they are also present in human 
plasma, glomerular disorders do not result in an increase in urinary concentrations 
[29-31]. Therefore it is proposed that urinary excretion of GST might be a reflection of 
the site of tubular injury when the tubular cell wall integrity is damaged. 
Renal replacement therapy
Approximately 5% of general ICU patients are treated with renal replacement therapy 
(RRT) which represents a substantial escalation in the complexity and cost of care for 
critically ill patients with AKI. Despite the extensive use in critical care practice there is 
uncertainty about the optimal time and indications for initiation of RRT in the ICU. Studies 
have shown marked variation of practice between clinicians and across institutions and 
countries mainly driven by logistic reasons [34, 35]. Currently there exists no broad 
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consensus to guide clinicians on this issue. With the emerging biomarkers and their 
predictive properties for AKI and its severity, they might be able to provide some 
guidance in determining more specific timing. 
Aim and outline of this thesis
The aim of this thesis was to asses the predictive value of several biomarkers of 
different origin for acute kidney injury in adult critically ill patients and to study their 
biological behaviour. Furthermore, we tried to answer why such experimentally proven 
highly sensitive markers have less predictive power in general critically ill patients. The 
basis of this thesis was founded by a prospective cohort study performed at the ICU 
of the Erasmus University medical center including 700 consecutively admitted adult 
critically ill patients, recruited from September 2007 till April 2008 for plasma and urine 
measurements. A sample and databank were created and several research questions 
were intended to be answered by the information generated form this dataset. In Part 
A we discern a describing part of the biological and pathofysiological background of 
biomarkers for AKI and an observational part where we describe the predictive ability of 
plasma and urine NGAL, plasma and urine Cystatin-C, urine KIM-1, urine Pi- and Alpha 
GST. Furthermore, we studied several confounding factors that affect the interpretation 
of biomarker values such as a systemic inflammatory response syndrome in severe 
sepsis and septic shock, the role of sampling time relative to the injurious renal hit and 
the site of renal injury. Part B describes a possible role of plasma NGAL in the decision 
to initiate renal replacement therapy and a clinical nomogram is proposed as a tool for 
clinicians to aid their decision to start early on (right after ICU admission) with renal 
replacement therapy.
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Research questions
1. What is the available evidence on different biomarkers predicting and diagnosing 
AKI in adult critically ill patients?
2. What is the predictive value of plasma and urine NGAL measured at ICU admission 
for AKI in general adult critically ill patients? Is there any additional value of both 
markers above serum creatinine and other clinical parameters? Is there additional 
value of serial measurements in this prediction?
3. Are plasma NGAL, urine NGAL, plasma CyC and urine CyC capable of differentiating 
between developing sustained AKI, developing transient AKI or no-AKI in adult 
patients at ICU entry? Does the prediction for sustained AKI improve when urine 
NGAL is combined with the other markers? 
4. What is the effect of severe sepsis and septic shock on plasma NGAL’s diagnostic 
ability for AKI?  
5. How does sampling time relative to the time of the injurious event affect the 
predictive ability of the urinary biomarkers NGAL, KIM-1, Pi- and Alpha GST? 
6. What is the clinical evidence for biomarkers aiding the prediction of need for renal 
replacement therapy and can we propose an algorithm in which biomarkers may aid 
in the timing of initiation of RRT?
7. Can we create a clinical scoring system for risk assessment of initiation of RRT that 
can aid a clinician in his decision to start RRT? 
8. What is the effect on plasma NGAL clearance during RRT applying a high cut-off 
hemofilter during continuous veno-venous hemofiltration? 
20 General introduction
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Abstract
Acute kidney injury (AKI) is strongly associated with increased morbidity and mortality 
in critically ill patients. Efforts to change its clinical course have failed because clinically 
available therapeutic measures are currently lacking, and early detection is impossible 
with serum creatinine (SCr).  The demand for earlier markers has prompted the 
discovery of several candidates to serve this purpose. In this paper we review available 
biomarker studies on the early predictive performance in developing AKI in adult 
critically ill patients. We make an effort to present the results from the perspective of 
possible clinical utility.
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Introduction
Acute kidney injury (AKI) represents an acute decline in renal function, which leads 
to structural changes. AKI is associated with increased mortality, length of hospital 
stay and costs [1]. This unfavorable outcome might be tied to the late detection of 
AKI when the elevation of serum creatinine (SCr) is used. Many genes are upregulated 
in the damaged kidney with the corresponding protein products appearing in plasma 
and urine. Some of these are candidate markers for more timely diagnosis of AKI. The 
purpose of this paper is to review the current state of epidemiological data concerning 
AKI, to evaluate available biomarkers for the prediction of AKI and to describe several 
potential therapeutic options. 
Epidemiology of AKI in crit ically i l l  patients
The Beginning and Ending supportive therapy for the Kidney investigators study (BEST 
Kidney study) has provided recent global insight as to the prevalence of patients with 
AKI. The reported mortality rate is 60.3%, with sepsis and premorbid renal dysfunction 
being dominant causes. In this observation, 13.8% of the patients with ARF surviving 
until hospital discharge required chronic renal replacement therapy (RRT) [2]. AKI and 
AKI requiring RRT display increasing incidence due to the rising degree of co-morbid 
conditions, increasing age and severity of illness in critically ill patients [3]. However, 
there seems to be a steady-state decline in annual in-hospital mortality (from 41.3% in 
1988 to 28.1% in 2002). Despite the observed reduction in mortality rates, the rising 
incidence of AKI comes at a price. Patients tend to survive the ICU but will be discharged 
with various degrees of chronic kidney disease (CKD), which will increasingly strain the 
health care system [4]. These data are supported by observations from Australia, where 
the 10-year trend in the incidence of AKI and the crude hospital mortality rates adjusted 
for illness severity were likewise investigated.  In this study 5.2% of the patients 
have AKI with an increased incidence over the past decade; however the multivariate 
adjusted odds of death associated with AKI shows a declining trend. The increased 
risk of death associated with AKI persisted with the adjustment for several relevant 
covariates. ARF exerts an independent, profound and specific effect on morbidity and 
mortality in critically ill patients [5]. Furthermore, outcomes are directly related to the 
severity of AKI: even small changes in SCr have a detrimental impact on patient long-
term survival [1, 6].
28 Chapter 1
Biomarkers for the prediction of AKI
The ability of biomarkers to predict AKI has been studied intensely in several different 
clinical settings. For a sound interpretation of the reported results, it is important to 
realize that the studies present a mixture of “AKI diagnosis confirmation” in patients with 
established AKI and “AKI early prediction” in patients with developing AKI. Obviously, 
these are two different entities with different clinical impacts. For the clinical application 
of a new biomarker it should prove to be more accurate with earlier detectability than 
the current gold standard SCr, which implies “early prediction” only.  Therefore, this 
review focuses on the prediction of developing AKI in adult critically ill patients. There 
are four major categories of biomarkers (Table 1). 
Functional markers
Serum creatinine (SCr)
Serum creatinine (SCr) is a degradation product of muscle cells and represents a 
surrogate for the efficiency of glomerular filtration. It has poor predictive accuracy for 
renal injury ,particularly, in the early stages of AKI [7]. In the case of critical illness, 
SCr concentrations are subject to large fluctuations due to a patient’s induced dilutional 
volume status, the catabolic effects of critical illness, the likelihood of concentration 
decreases in septic conditions and the increased tubular excretion with diminishing 
renal function. Furthermore, after an injurious event, the rise in SCr is slow. Therefore, 
detection of the earliest evidence of AKI necessitates the use of other plasma or urinary 
biomarkers. 
Plasma/serum Cystatin-C (CyC)
Cystatin C (CyC) is a 13-kDa nonglycosylated cysteine protease inhibitor produced 
by all nucleated cells at a constant rate. In healthy subjects, plasma CyC (pCyC) is 
excreted through glomerular filtration and metabolized completely by the proximal 
tubules. Furthermore, there is no evident tubular secretion. Several studies claim the 
superiority of pCyC against SCr to detect minor reductions in GFR [8]. However, the 
interpretation of pCyC levels is biased by older age, gender, weight, height, cigarette 
smoking and high levels of CRP [9, 10]. In addition, CyC levels are supposedly 
influenced by abnormal thyroid function [11, 12] the use of immunosuppressive therapy 
[13] and malignancies [14, 15]. In 318 patients included at ICU admission, pCyC 
predicted developing sustained AKI (n=19) very modestly (AUC= 0.65 [ CI 0.58-0.71] 
in univariate analysis [16]. Herget-Rosenthal described a cohort in whom sCyC was 
measured at admission in 85 patients with normal GFR. The reported AUC was 0.82 [CI 
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0.71-0.92] for acute renal failure two days prior to the event [17]. A recent multicenter 
study in 151 subjects in a comparative setting found a poorer performance (AUC= 0.72 
no CI provided) [18]. Metzger et al. compared the classification performance of a set of 
urinary proteome analyses with sCyC in 20 general ICU patients, retrospectively, and 
found low classification accuracy (AUC = 0.67 CI not provided) [19]. 
In cardio pulmonary bypass (CPB) cohorts, several studies explored the use of CyC for 
AKI prediction. Haase-Fielitz et al. described 100 cardiac surgical patients among whom 
23 subjects were classified as patients without preoperative renal impairment. Their 
samples were measured at ICU arrival, and the reported AUC= 0.78 [CI 0.58-0.99] 
did not improve after 24 hours [20]. Koyner et al. reported on 72 patients who were 
admitted following CPB with 34 subjects developing AKI, which was defined as a 25% 
increase in pCr or the need for RRT (n=7) within 3 days after surgery. PCyC measured 
at time of ICU arrival was not a useful early predictor for the composite outcome AUC= 
0.62 [0.49-0.75] [21]. A likely explanation is the applied unusual definition of AKI, 
which indicates less severe grades of AKI among the event group.  
Upregulated proteins
Neutrophil Gelatinase-Associated Lipocalin (NGAL)
NGAL is a small protein linked to neutrophil gelatinase in specific leukocyte granules 
[22]. It is also expressed in a variety of epithelial tissues associated with antimicrobial 
defense [23-26]. In the normal kidney, only the distal tubules and collecting ducts 
stain for NGAL expression. NGAL’s composite molecule binds ferric siderophores, and 
furthermore, it is a potent epithelial growth inducer, has protective effects in ischemia 
[27] [28] and is upregulated by systemic bacterial infections [24, 29-32]. In case of AKI, 
proximal tubule cells also stain for NGAL proteins, which is explained by megalin-cubulin 
mediated re-uptake of NGAL present in the glomerular filtrate [33] [34]. Urinary NGAL 
originates from local production in the distal tubules and collecting ducts. However, 
uNGAL excretion is proportional to albumin excretion in mouse models of diabetic 
nephropathy and is thus augmented when the proximal transport maximum is exceeded 
[33, 35, 36]. Siew et al. enrolled their patients within 24 hours after admission and 
reported a ROC AUC=0.77 [CI 0.64-0.90] for developing AKI in a subgroup of patients 
with eGFR at admission > 75 ml/min/1.73m2 for urine NGAL (n=18 vs. 257)[37]. Cruz et 
al. reported on the development of AKI within 48 hours after first sampling an AUC=0.78 
[CI 0.65-0.90]. However, the reported PPV was low (24%), and within 5 days, the AUC 
was reduced to 0.67 [CI 0.55-0.79] [38]. The first sampling was performed within 
24 hours after ICU admission. De Geus et al. came to roughly similar reports with 
samples at ICU admission in patients with eGFR > 60ml/min/1.73m2 for both plasma 
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and uNGAL (AUC=0.75±(SE) 0.103) AUC NGAL=0.79±(SE) 0.085  [39]. It is debatable 
whether the exclusion of patients with eGFR’s below 75 or 60 ml/min/1.73m2 applied by 
Siew and de Geus et al. is useful in clinical practice, because a biomarker should also 
be effective in patients with CKD. In patients with sepsis, the predictive performance 
for AKI seemed not to be affected, as reported by Martensson for both plasma and 
urine NGAL (respectively, AUC’s= 0.85 [CI 0.67-1.0] and 0.86 [CI 0.68-1.0]) [40]. 
However, Bagshaw et al report a distinct influence on test characteristics in patients with 
sepsis [41]. Several studies report results in CPB cohorts: Koyner et al. measured both 
pNGAL AUC 0.526 [0.388-0.664] and uNGAL AUC= 0.705 [CI 0.581-0.829] [21] at ICU 
admission. An additional analysis by the same authors stratified their patients according 
to attained RIFLE stage and reported increased performances when using the harder 
endpoint of Failure  AUC=0.69 [0.57-0.80] and AKIN stage 3 AUC= 0.79 [0.65-0.94] 
[42]. A large study (n= 426) in CPB patients demonstrated test performance association 
with the pre-surgery baseline eGFR. Interestingly, only in patients with an eGFR above 
60 ml/min was NGAL predictive: AUC=0.68 [CI 0.54-0.81] [43]. A much smaller 
study (n=9 events) reported values for both pNGAL and uNGAL, corrected for urinary 
creatinine: AUC= 0.85[CI 0.73-0.97] and AUC= 0.96 [CI .90-1.0], respectively [44]. 
Haase-Fielitz compared the performance of conventional and novel markers for pNGAL 
in adult CPB patients, excluding patients with preoperative renal impairment NGAL: the 
results yielded AUC=0.80 [CI 0.58-0.99] [20].  In another large study (n=8790) for 
pNGAL measured immediately after CPB with 75 events, the AUC reported was 0.641 
[0.58-0.71] [45]. Wagener et al. performed a study in adult CPB patients: for urine 
NGAL, the predictive performance was AUC=0.573 [CI 0.506-0.640] directly after the 
operation: the performance increased until 18 hours after ICU admission to a maximum 
of 0.611 [46]. In a study performed by Liangos et al. these results were similar in 103 
CPB patients 2 hours after surgery: AUC= 0.50[CI 0.33-0.68] [47].  Among general 
adult ICU patients, 82 subjects developed AKI within 48 hours of admission, and the 
predictive performance for NGAL corrected for urinary creatinine concentration yielded 
AUC=0.55 [CI 0.48-0.63] [48]. Metzger et al. compared the classification performance 
of urinary proteome analysis with classical markers. For urine NGAL, the ROC analysis 
revealed low classification accuracy: AUC = 0.54 CI (not provided) [19]. The only meta-
analysis published to date assessed pNGAL‘s ability to predict across different settings; 
when weighted for study sample size, this value yielded an overall AUC of 0.782 [CI 
0.689-0.872]. [49].
Kidney Injury Molecule-1 (KIM-1)
Kidney Injury Molecule-1 (KIM-1) is a type I transmembrane glycoprotein with a cleavable 
ectodomain (90 kDa) which is localized in the apical membrane of dilated tubules in acute 
and chronic injury [50, 51]. Kim-1 is believed to play a role in regeneration processes 
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after epithelial injury and in the removal of dead cells in the tubular lumen through 
phagocytosis [50, 52]. A reduction in proteinuria with RAAS blockade is accompanied by 
a reduction in urinary KIM-1 excretion [53, 54].  Among general adult ICU patients, 82 
subjects developed AKI within 48 hours of admission, and the predictive performance 
for KIM-1  corrected for urinary creatinine concentration  yielded AUC=0.55 [CI 
0.47-0.62] in the study of Endre et al [48]. Metzger et al. compared the classification 
performance of urinary proteome analysis with classical markers. For urine KIM-1, the 
ROC analysis revealed low classification accuracy (AUC = 0.71 CI, not provided) [19]. 
Several studies report its diagnostic properties in adult CPB patients [42, 47, 55-57] . 
Liang et al. reported an AUC for progressive AKI of 0.69 [CI 0.61-0.78] after 6 hours of 
inclusion. Notably, adding KIM-1 to IL-18 (AUC for IL-18 for progressive AKI 6 hrs after 
inclusion was 0.87 [CI 0.80-0.93]) in a predictive model improved the model’s accuracy 
only minimally (AUC 0.88 [CI 0.82-0.93]). Liangos et al. reported an AUC 2 hours 
post-CPB surgery of 0.78 [CI 0.64-0.91]: however, in multivariate regression analysis, 
the association of KIM-1 was attenuated after adjustment. Koyner et al. found an AUC 
0.56 [CI 0.45-0.67] as admission value for the entire cohort with an improvement when 
predicting AKIN stage 3 only (AUC=0.69 [CI 0.44-0.93]) [42].  
Liver Fatty Acid Binding Protein (L-FABP)
Fatty Acid Binding Proteins are small (15 kDa) cytoplasmatic proteins abundantly 
expressed in tissues with active fatty acid metabolism.  Their primary function is the 
facilitation of long-chain fatty acid transport, the regulation of gene expression and the 
reduction of oxidative stress.  Urinary L-FABP is undetectable in healthy control urine, 
which is explained by efficient proximal tubular internalization via megalin-mediated 
endocytosis [58] [59]. Under ischemic conditions, tubular L-FABP gene expression is 
induced; in renal disease, the proximal tubular re-absorption of L-FABP is reduced [59, 
60]. To date, there is one small study reporting on the early diagnostic performance of 
L-FABP in adult ICU patients. The reported ROC AUC value was 0.95, no CI provided. 
However, several uncertainties remain after disclosure of the study’s methodology. First, 
patient selection (n=25 with 14 AKI and 11 non-AKI) seems to have been a result of 
convenient sampling. Second, the “true early diagnosis” remains very doubtful as peak 
SCr and L-FABP values are reported as having the same median value; no further clear 
information concerning timing is provided [61].
Interleukin -18
In animal models, Interleukin-18 (IL-18) has proven to be an important mediator in the 
process of AKI. Therefore, its urinary release has been anticipated as a possible early 
marker: several studies have explored the clinical application of this hypothesis. 
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Among general adult ICU patients, 82 subjects developed AKI within 48 hours of 
admission, and the predictive performance for IL-18 corrected for urinary creatinine 
concentration was AUC=0.55 [CI 0.47-0.62] [48]. Metzger et al. compared the 
classification performance of urinary proteome analysis with classical markers. For 
urine Il-18, the ROC analysis revealed low classification accuracy (AUC = 0.57 CI not 
provided) [19]. Nevertheless, in a large cohort of mixed patients (n=451) Siew et al. 
enrolled patients within 24 hours after ICU admission: 86 developed AKI. The overall 
predictive performance reported was AUC=0.62 [CI 0.54-0.69]; this value increased 
slightly in patients with an eGFR above 75 ml/min/1.73m2 (AUC= 0.67 [CI 0.53-0.81]). 
There seemed to be a strong association with sepsis [62]. In patients with acute lung 
injury (ALI), uIL-18 predicted progression to AKI within 24 hours with an accuracy of 
AUC=0.731 (CI not provided) with substantial overlap between cases and controls in 
urine concentrations [63]. In CPB patients, 2 hr after CPB time, the optimal performance 
was reported to yield an AUC= 0.66 [CI 0.49-0.83][47]. 
Low molecular weight proteins
Urine Cystatin C
The urinary excretion of CyC (uCyC) specifically reflects tubular damage because 
systemically produced Cystatin C is normally not found in urine [64]. However, recent 
insights show that urinary CyC excretion is augmented by albuminuria [65] In patients 
without AKI on ICU entry, uCyC was not predictive of AKI occurring within 48 hours 
with AUC= 0.54 [CI 0.46-0.62] [66]. Liangos et al. used uCyC for this prediction, which 
resulted in very moderate performances 2 hours post-CPB surgery with ROC AUC= 
0.50 [CI 0.27-0.72] in a cohort of 103 patients with 13 events of AKI [47].  In a study 
in patients undergoing CPB, Koyner et al. demonstrated that uCyC measured at ICU 
admission reached a maximum performance with an AUC of 0.693 [CI 0.567-0.818]. 
[21][48] Among general adult ICU patients, 82 subjects developed AKI within 48 
hours of admission and the predictive performance for urine CyC corrected for urinary 
creatinine concentration yielded AUC=0.55 [CI 0.48-0.63]. Another study performed by 
Koyner et al. demonstrated the predictive value of uCyC at ICU admission for any stage 
of AKI with AUC=0.72 [CI 0.61-0.83]. For the prediction of AKIN stage 3 vs. the rest 
of the cohort, the predictive performance increased to AUC=0.84 [CI 0.68-0.99] [42]. 
Royakkers et al. regarded uCyC as a predictor for AKI 2 days prior to the first day of AKI 
and found no diagnostic value (AUC=0.49 no CI provided) [18]. 
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Tubular Enzymes
Alpha-Glutathione s-transferase (α-GST) and Pi-Glutathione s-transferase 
(π-GST)
Alpha-Glutathione s-transferase (α-GST) and Pi-Glutathione s-transferase (π-GST) 
are both members of a multigene family of detoxification enzymes present in many 
organs including the kidney. Distribution across the entire nephron of structurally and 
functionally distinct isoforms has been demonstrated. In urine, these enzymes are 
normally not present. After injury, α-GST is primarily detected in the proximal cells, 
whereas π-GST is observed in the distal parts [67]. Westhuyzen et al. studied the 
predictive performance of tubular enzymes and their combination in adult critically ill 
patients. Four patients developed AKI defined as a 50% SCr increase or more.  At the 
time of ICU admission, α-GST and π-GST measured and indexed to urine creatinine 
provided AUC’s of 0.893 [ CI 0.688-0.975] and 0.929 [ 0.740-0.990] respectively. 
[68]. However, the patients with AKI seemed to have established AKI at study inclusion 
with a median creatinine clearance of 38.1 ml/min.  Walshe et al. reported that in 
patients with developing AKI and sepsis admitted to the general ICU, both enzymes 
were bad predictors. They suggested that sepsis might be the confounder triggering 
the production of these enzymes [69]. Finally, a study by Koyner et al. in 123 adult 
CPB patients reported AUC=0.59 [CI 0.47-0.71] and 0.54 [0.42-0.66] for the prediction 
of AKI stage 1 for α-GST and π-GST measured at ICU unadjusted for urine creatinine 
arrival, respectively, with similar test performances when using the harder endpoint of 
AKIN stage 3 AUC= 0.58 [0.31-0.85] and AUC= 0.70 [0.50-0.90] [42] .
Gammaglutanyl transpeptidase (GGT) and Alkaline Phosphatase (AP)
Gammaglutanyl transpeptidase and alkaline phosphatase both are tubular brush border 
enzymes that are released into urine when there has been significant damage to the 
brush border membrane with loss of the microvillus structures. Few clinical studies are 
available, but Westhuyzen et al. report data on 4 cases with developing AKI respectively 
of AUC= 0.950 [CI 0.789-0.999] and AUC= 0.863 [CI 0.676-0.973] [68]. However, 
these results should be interpreted with caution, because the cases must be considered 
as established AKI at study inclusion according to their reported creatinine clearance. In 
general adult ICU patients, 82 subjects developed AKI within 48 hours of admission and 
the predictive performance for urine GGT and urine AP corrected for urinary creatinine 
concentration AUC=0.57 [CI 0.50-0.64]  and AUC 0.56 [CI 0.49-0.63], respectively 
[48]. 
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N-acetyl-β-D-glucosaminidase (NAG)
N-acetyl-β-D-glucosaminidase (NAG) is a lysosomal enzyme (> 130 kDa) that is localized 
in the renal tubules. Due to its large molecular weight, it precludes glomerular filtration, 
implying that urinary elevations have a tubular origin. Increased activity suggests injury 
to its cells but may also reflect increased lysosomal activity without cell disruption. 
NAG catalyzes the hydrolysis of terminal glucose residues in glycoproteins. Westhuyzen 
reported on the ability to predict developing AKI in 4 cases in general ICU patients 
with AUC=0.845 [CI 0.639-0.955]: however, these patients seem to have established 
AKI with reduced creatinine clearance at the time of study inclusion [68]. In adult 
CPB patients, 13 cases of developing AKI were reported: and the 2-hr postoperative 
prediction for NAG was very moderate: AUC=0.62 [CI 0.41-0.83] [47]. 
Treatment of AKI
The pathogenesis of AKI is very complex with multiple mechanisms underlying its course. 
Furthermore, critically ill patients do not generally die from AKI as such but more from 
the multiple organ dysfunction syndrome (MODS) associated with it. Given the multiple 
interactive pathways underlying AKI, it might be a mistake to concentrate therapeutic 
effects on one single part of the interrelated cascades. Therapies may need to target 
multiple sites in the pathophysiological pathways of AKI and MODS in order to be of 
any benefit for patients. Such combination therapies must involve agents with potential 
beneficial effects on vascular tone, tubular obstruction, and inflammation. Furthermore, 
it is unlikely that targeting events that occur late in AKI will be effective.  Pharmacological 
therapy in the prevention and treatment of AKI has been largely unsuccessful despite 
proven benefits as seen in preclinical studies. A number of drugs and investigational 
compounds seem promising in preclinical studies.  There are six major categories of 
treatment strategies: anti-inflammatory agents, anti-apoptotic agents, iron scavengers, 
anti-oxidants, vasodilators and growth factors (Table 2). 
Conclusions
In the quest for earlier markers for the recognition of AKI several biomarkers have been 
investigated. The reported AUC’s are disappointing ranging from 0.50-0.84, with one 
or two exceptions which can be explained by statistical or methodological differences 
in study design. The discriminatory function in heterogeneous populations is poor and 
influenced by pre-existing renal function and time of sample collection with respect to 
the renal insult [48]. Clinical appraisal of a patient and using standard parameters such 
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as SCr and diuresis remains the cornerstone for now [70]. Therefore it seems reasonable 
to perhaps shift our views and using biomarkers together with other parameters such 
as traditional clinical characteristics to optimize the accuracy of prediction of developing 
AKI might be an interesting option. Ultimately, the potential of new therapeutic agents 
can be tested and their use evaluated. 
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At a glance commentary:
Acute kidney injury is an independent risk factor for ICU mortality. The current gold 
standard for detection of AKI, serum creatinine, is not a perfect biomarker. Measuring 
other biomarkers, such as NGAL, may have the potential to aid in improved outcomes in 
patients with AKI because of earlier and more accurate prediction. 
This study shows that NGAL, an injury biomarker, can accurately predict the development 
of AKI in adult ICU patients, that combining NGAL with other clinical predictors improves 
this prediction, that serial NGAL measurements do not improve the prediction for severe 
AKI and that sepsis is a trigger for urine NGAL production. 
Abstract
Rationale: Measured at ICU admission, the predictive value of neutrophil-gelatinase- 
associated-lipocalin (NGAL) for severe acute kidney injury (AKI) is unclear.
Objective: To assess the ability of plasma and urine NGAL to predict severe AKI in adult 
critically ill patients.
Design: Prospective-cohort-study.
Patients: 632 consecutive patients  
Measurements: Samples were analysed by Triage® immunoassay for NGAL expression. 
The primary outcome measure was occurrence of AKI based on RIFLE classification 
(Risk-Injury-Failure) during the first week of ICU-stay.  
Results: A total of 171 (27%) patients developed AKI. Of these 67, 48 and 56 were 
classified as RIFLE R, I and F respectively. Plasma and urine NGAL values at ICU 
admission were significantly related to AKI severity. The areas under the ROC curves 
for plasma and urine NGAL were for RIFLE R (0.77±0.05 and 0.80±0.04 respectively), 
RIFLE I (0.80±0.06 and 0.85±0.04 respectively) and RIFLE F (0.86±0.06 and 0.88±0.04 
respectively) and comparable to those of admission estimated-glomerular-filtration-rate 
(eGFR) (0.84±0.04, 0.87±0.04 and 0.92±0.04 respectively). Plasma and urine NGAL 
significantly contributed to the accuracy of the “most efficient clinical model” with the 
best 4 variables including eGFR, improving the AUC’s for RIFLE F prediction to 0.96±0.02 
and 0.95±0.01. Serial NGAL measurements did not provide additional information for 
the prediction of RIFLE F. 
Conclusion: NGAL measured at ICU admission predicts the development of severe AKI 
similarly to serum-creatinine-derived eGFR. However NGAL adds significant accuracy to 
this prediction in combination with eGFR alone or to other clinical parameters and has 
an interesting predictive value in patients with normal serum creatinine. 
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Introduction
In critically ill patients, acute kidney injury (AKI) is independently associated with 
increased costs of medical care, as well as increased risk of morbidity and mortality 
[1-4]. In addition, when AKI develops during hospital admission it results in accelerated 
progression towards end-stage renal disease (ESRD), especially in elderly patients [5]. 
Recent observational studies have shown a 14% incidence of dialysis dependency at 
the time of hospital discharge among survivors of critical illness [3]. Therefore, early 
recognition of renal injury is important and may help prevent further renal damage and 
functional impairment. 
Recent experimental [6-8] and clinical [9-11] studies have identified biomarkers that 
may serve as early indicators of AKI. Of these, neutrophil gelatinase-associated lipocalin 
(NGAL) seems to be the most promising. NGAL is a 25-kDa protein that is covalently bound 
to gelatinase and is secreted from human neutrophils [12]. It is generally expressed at 
low concentrations in various organs containing epithelial tissues, including the kidney. 
When acute tubular damage occurs it is rapidly expressed at high concentrations in both 
plasma and urine. [7-9, 13].
The first clinical validation was carried out in pediatric cardiac surgery patients [9]. 
In this study NGAL measured two hours after surgery was an excellent predictor of 
AKI whereas serum creatinine (SCr) did not start to rise until 24 to 72 hours following 
surgery. However, in settings in which the initiation of renal injury is unclear, such as 
in cases of sepsis, trauma, acute and critical illness, the predictive value of plasma 
and urine NGAL is less certain [13-19]. Furthermore, whether NGAL on its own or in 
combination with clinical parameters can be of additional value for the prediction of 
severe AKI has yet to be determined. 
We therefore, conducted a prospective study in a large cohort of adult ICU patients to 
assess the predictive value of plasma and urine NGAL levels at the time of admission 
with regard to the development of severe AKI during the early days of ICU treatment 
and their extended contribution in early diagnosis beyond eGFR. None of the results of 
this current study have been previously reported in abstract form. 
Patients and Methods
A detailed method session is given in the online data supplement (ODS)
Patients
The EMC institutional review board of the approved the study. All consecutive admitted 
patients between September 2007 and April 2008 were eligible for enrollment. Exclusion 
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criteria included age under 18 years, refusal of consent, nephrectomy, chronic kidney 
disease (CKD), end stage renal disease (ESRD) and renal transplantation. Deferred 
consent was used, and written informed consent was obtained from all participants or 
their heath care proxy [20]. 
Procedures
Following admission, plasma and urine samples were collected (T=0) and thereafter at 
4, 8, 24, 36, 48, 60 and 72 hours. Missing admission (T=0) samples were replaced by 
first collection values at either 4 or 8 hours after admission. Plasma and urine NGAL 
were measured on the Triage® NGAL Test point-of-care fluorescence immunoassay in a 
laboratory, blinded to patient clinical data (Biosite Inc, San Diego USA). The Triage NGAL 
test has been validated against an NGAL ELISA assay [21] (Detailed assay description 
ODS-1&2). Serum creatinine (SCr) was measured at admission and thereafter daily 
at 6:00 am. The estimated glomerular filtration rate (eGFR) was calculated using the 
Modification of Diet in Renal Disease Study Equation (MDRD) (ODS 3) [22]. Baseline SCr 
was defined as the steady state level four weeks prior to admission. If not available, the 
admission value was used as a surrogate baseline. Other variables included age, gender, 
body mass index (BMI), temperature, pH, bicarbonate, potassium, blood urea nitrogen 
content (BUN), white blood cell count, C-reactive protein and lactate. For disease severity 
assessment, the Acute Physiology and Chronic Health Evaluation score (APACHE II) and 
the sequential organ failure assessment score (SOFA) were used. Furthermore, the 
cumulative urine output, initiation of renal replacement therapy (RRT), ICU-days, ICU 
mortality and hospital mortality were recorded. The primary outcome variable was AKI 
occurring within seven days after ICU admission  according to the RIFLE (Risk-Injury-
Failure) classification [23]. The RIFLE classification is based on the rise in SCr compared 
to a baseline value. Risk represents a 1.5-2 times increase, Injury a 2-3 times increase 
and Failure a more than 3 times increase.
Statistical analysis
MATLAB version 7.5.0 and SPSS version 16.0 were used. The relationships between 
AKI and NGAL levels were assessed using the Mann-Whitney U test and the chi-square 
test. Continuous variables were described by medians and interquartile ranges. Receiver 
operating characteristic (ROC) curves with their area under the curve (AUC) with two 
times its standard error (2SE) was calculated. Uni-and multivariable logistic regression 
analyses were used to assess the predictive value of NGAL in combination with clinical 
parameters.  Statistical significance was assessed by estimating the standard error 
of its coefficient and conducting a Wald-test of the null hypothesis. Stepwise forward 
likelihood ratio regression was used to determine the model’s most efficient predictors. 
Goodness of fit was assessed using the Hosmer-Lemeshow test. The net reclassification 
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improvement (NRI) was calculated. All reported p–values are two-tailed, and p-values 
< 0.05 were considered statistically significant. 
Role of funding source
Biosite Incorporated (San Diego, CA, USA) provided biomarker measurements and 
statistical support. They had no role in study design, data collection or writing of the 
manuscript. The first author had full access to all data and had final responsibility to 
submit for publication. 
Results
Patient characteristics
Of the 700 consecutive patients who were screened for inclusion in the study, 68 (9.8%) 
were excluded because of refusal of consent (n=6), nephrectomy (n=6), CKD, ESRD and 
kidney transplantation (n=25) or missing admission data (n=31). Thus, 632 (90.2%) 
patients were included in the analysis. Patient characteristics are shown in Table 1. AKI 
occurred in 171 patients (27%). Of those patients, 67 developed RIFLE R, 48 patients 
developed RIFLE I and 56 patients developed RIFLE F. The time to reach a SCr increase 
of more than 50% compared to baseline for the first time (=RIFLE R) was T=0 in 58.5% 
of the patients, T=24 in 24.0%, T=48 in 6.4% and T=72 in 5.8% of the patients. Thus 
94.7% of the patients reached “first AKI” within 72 hours after ICU admission. Twenty-
eight (50%) of the AKI patients in the RIFLE F class received RRT (4.4% of the overall 
patient cohort). Baseline characteristics in all RIFLE classes were compared with subjects 
who did not develop AKI. There were no differences with respect to age, gender or BMI. 
Patients with AKI had higher APACHE II and SOFA scores than patients without AKI (Table 
1). Furthermore, there were positive correlations between the severity of kidney injury 
and length of stay, ICU mortality and hospital mortality (Table 1). The incidence of AKI was 
higher in patients admitted after cardiopulmonary resuscitation (CPR) was performed, as 
well as in patients with sepsis or multi-organ failure syndrome (p < 0.0001) (Table 1). 
Association between NGAL and AKI development
Patients’ plasma and urine NGAL concentrations at the time of ICU admission were 
significantly related to their RIFLE scores (p< 0.0001, Table 1, Fig.1). The plasma 
NGAL test performance for predicting the severity of AKI in the entire cohort showed 
an AUC of 0.77±0.05 for RIFLE R and above, 0.80±0.06 for RIFLE I and above and 
0.86±0.06 for RIFLE F. Similar analysis for urine NGAL revealed AUC’s of 0.80±0.04 
(RIFLE R), 0.85±0.04 (RIFLE I) and 0.88±0.04 (RIFLE F) (Fig.2A and B). The differences 
between the plasma and urine AUCs were not significant. The AUC’s and ROC curves 
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Figure 1: Admission plasma (A) and urine (B) NGAL concentrations stratified by RIFLE classification. An ex-
ploratory Mann-Whitney U test of adjacent categories, including non-AKI vs. R, R vs. I, and I vs. F, resulted 
in p-values of <0.0001, 0.10, and 0.0005, respectively, for plasma NGAL and <0.0001, 0.028 and 0.001, 
respectively, for urine NGAL.
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Figure 2: ROC curve analysis for the ability of admission plasma (A) and urine (B) NGAL, eGFR (C) 
to predict AKI, stratified by RIFLE classification. With panel (D) showing both plasma and urine 
NGAL’s predictive properties for RIFLE I or worse in patients with eGFR above 60 mL/min/1.73 m2. 
AUC values ± 2SE are presented parenthetically after the RIFLE classification.
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Figure 3: Admission plasma (A) and urine (B) NGAL values for patients without AKI stratified by diagnostic 
groups.
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for eGFR predicting AKI stratified for RIFLE stage are shown in Fig. 2C. Comparing 
the performance of eGFR to plasma and urine NGAL showed that only plasma NGAL 
predicting R and above, or I and above were significantly different compared to the 
corresponding AUC’s of eGFR (p=0.015 and p= 0.039). Table 2 lists the calculated 
sensitivities at fixed specificities of 50, 70 and 90% (derived by visual inspection of the 
ROC curves) with the corresponding cut-off concentrations of plasma and urine NGAL 
for the prediction of RIFLE F. 
Association between NGAL and AKI development in patients with eGFR > 60 
mL/min/1.73 m2
In order to determine the potential additional contribution of NGAL as a biomarker 
predicting AKI before SCr has started to rise and consequently eGFR has started to 
decline a subset analyses was performed in patients with apparently normal renal 
function  (n=498) at the time of ICU admission (i.e. excluding patients with an eGFR< 
60 mL/min/1.73 m2). ROC analysis demonstrated that in patients who did not show any 
increase in SCr yet at ICU admission, plasma and urine NGAL had diagnostic superiority 
over SCr and eGFR for predicting severe AKI (RIFLE I and F). The AUC’s for plasma 
and urine NGAL were respectively 0.75±0.10, 0.79±0.10 compared to 0.65±0.10 and 
0.67±0.10 for SCr and eGFR respectively (Fig. 2D)
Relative contribution of NGAL to the most efficient clinical prediction model at 
admission for prediction of RIFLE F
Adding pNGAL and uNGAL to eGFR in a multivariable logistic regression model improved 
the prediction significantly (p<0.001). To determine the added contribution of NGAL 
to eGFR and other available clinical variables at ICU admission for predicting the 
occurrence of RIFLE F within the first week of patients’ ICU stay, additional logistic 
regression analysis was performed (Table 3). The available clinical predictors included 
age, BMI, temperature, diagnosis of sepsis, pH, bicarbonate, potassium, BUN, white 
blood cell count, CRP and lactate. Adding NGAL to eGFR and clinical variables improved 
the prediction significantly for pNGAL (p=0.014) and almost significantly for uNGAL 
(p= 0.092). Using a stepwise forward likelihood ratio logistic regression NGAL, eGFR, 
diagnosis of sepsis, white blood cell count (WBC) and temperature on admission made 
the most efficient clinical model for the prediction of RIFLE F for plasma out of the 
available variables in this study. For urine the most efficient model comprised NGAL, 
eGFR, diagnosis of sepsis and WBC (Table 4). Adding NGAL changed the model’s AUC’s 
from 0.95±0.02 to 0.96±0.02 for plasma NGAL and 0.94±0.02 to 0.95±0.01 for urine 
NGAL. Furthermore, we assessed the ability of plasma and urine NGAL to “reclassify” 
the degree of risk for RIFLE F within 7 days as assessed by the model. Subjects were 
categorized into prespecified “low”, “medium” and “high risk” groups using cut-offs of 
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<30%, 30-60% and >60% respectively. We compared the proportions of reclassified 
subjects across these three risk groups when NGAL was added to the clinical model for 
plasma and urine (ODS-4 for detailed reclassification table). For 5 patients with RIFLE 
F reclassification was more accurate when the model with all 4 variables for pNGAL was 
used and for 2 patients it became less accurate. Among the subjects without RIFLE F, 9 
were correctly reclassified in a lower risk category while 3 were incorrectly reclassified to 
be at higher risk. The same analysis was performed for uNGAL (ODS-4). The generated 
net reclassification improvement (NRI) for plasma and urine NGAL added to the clinical 
prediction model was 8.5% (p=0.087) and 2.3% (p=0.370) respectively.
Relative contribution of serial NGAL measurements to the most efficient 
clinical prediction model for prediction of RIFLE F
The progression of mean plasma and urine NGAL concentrations stratified by RIFLE 
classification over time is shown in the ODS-5 (Fig. E1 and E2). To determine if serial 
sampling could be of additional value for the prediction of RIFLE F plasma and urine 
NGAL values and those of the other predictors at T=0 and T=24 (temperature, pH, 
bicarbonate, potassium, BUN, WBC, CRP, lactate) were used for multivariable logistic 
regression analysis. In addition, age, BMI, diagnosis of sepsis, eGFR MDRD T=0, the 
24-hour urine production, the 24-hour cumulative fluid balance, APACHE II and SOFA 
score were added. All subjects with established RIFLE F or missing data in first 24 hours 
were excluded, leaving 429 patients for the plasma and 411 for the urine analysis. With 
stepwise forward likelihood ratio logistic regression the most efficient predictors were 
pNGAL T=24 (p=0.000) and CRP T=0 (p=0.024) for the plasma NGAL model. Adding 
pNGAL T=24 changed the model’s AUC from 0.63±0.04 to 0.91±0.03, underlining that 
pNGAL T=24 is a very strong predictor for RIFLE F. For urine, the model showed NGAL 
T=24 (p=0.001), Temp T=0 (p=0.02), APACHE T=24 (p=0.011), UP T=24 (p=0.009), 
pH T=24 (p=0.005) and potassium T=0 (p=0.055) as most efficient predictors. Adding 
uNGAL T=24 changed the model’s AUC from 0.84±0.06 to 0.93±0.04. Assessment of 
both plasma and urine NGAL values’ difference scores in the logistic regression analysis 
showed that the temporal changes were not relevant; pointing out that the NGAL value 
measured closer to the endpoint “RIFLE F” was the strongest predictor of all. Analyzing 
further contribution of serial measurements over the succeeding time points was not 
possible due to the significant reduction in sample size with the diminished availability 
of equal measurements. Furthermore since the difference in serial measurements in the 
first 24 hours did not add to the prediction of RIFLE F, it is not expected that the results 
will be different when analyzing subsequent time points.
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Association of NGAL and sepsis in patients without AKI
In patients with sepsis (n=14) who did not develop AKI, urine NGAL levels were 
significantly higher than those of patients in the other diagnostic groups. The median 
NGAL value was 1264.1 ng/ml (650.3, 4124) (Fig.3). In the group of 14 septic non-AKI 
patients, one received renal drainage because of obstructive hydronephrosis, one had 
a positive urine culture with Acinetobacter species, one had a positive white cell and 
nitrite count in the urine sediment without a positive culture already under antibiotic 
treatment and one patient had a proven renal abscess with E. Coli. After we adjusted 
the urine NGAL analysis removing those patients and patients who died within 48 hours 
after admission to the ICU, urine NGAL levels were still significantly higher among 
patients with a diagnosis of sepsis than among patients in the other diagnostic groups 
(p=0.0005).
Association between NGAL and RRT or mortality
In the entire cohort both NGAL plasma and urine values were predictive of RRT initiation 
within the first week of ICU admission (respectively AUC 0.88±0.06 and AUC 0.89±0.04). 
However, SCr and eGFR reached similar performances (respectively AUC 0.90±0.05 
and 0.91±0.05). Both plasma and urine NGAL have a minor role in predicting hospital 
mortality with very modest performances (AUC 0.63±0.06 and AUC 0.64±0.06). 
Discussion
The present study shows that plasma and urine NGAL levels at time of ICU admission 
predict the development of severe AKI and the initiation of RRT in critically ill patients 
within the first 7 days of their ICU stay. Furthermore, adding NGAL values to a model 
with eGFR alone or to the most efficient clinical model with available parameters 
improves the prediction significantly. Using serial NGAL measurements did not provide 
additional accuracy in the prediction of RIFLE F. Finally, non-AKI patients with sepsis 
have significantly higher urinary NGAL values compared to other non-AKI patients.
NGAL fulfills a central role in regulating epithelial neogenesis, as well as in iron chelation 
and delivery after ischemic or toxic insults to the renal tubular epithelium [24, 25]. 
Following kidney injury, NGAL is rapidly expressed on the apical epithelial membranes 
of the distal nephron. NGAL is excreted in the urine through exocytosis and has local 
bacteriostatic and pro-apoptotic effects [26, 27]. Plasma NGAL is easily filtered by 
the glomerulus and reabsorbed in the apical membranes of the proximal tubules. 
Reabsorbtion is mediated by megalin/cubulin dependent endocytosis with a very high 
affinity. The delivered iron is needed in processes activating and repressing iron-
responsive genes that are vital to the regeneration processes that occur after damage 
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is inflicted to these cells. Under normal circumstances the estimated half life of plasma 
NGAL is approximately 10 minutes, with urinary loss <0.2% [28, 29]. Plasma and urine 
NGAL concentrations increase by 10- to 100- fold during the 2 hours that follow tubular 
injury[7-9], whereas serum creatinine does not start to rise 24 to 72 after the initial 
renal insult [9, 16, 30].
Because we are interested in the possible prevention of (further) kidney injury in 
critically ill patients, AKI was assessed only during the first week of each patient’s ICU 
stay in order to link the condition of the patient at the time of admission and the initial 
resuscitation efforts to the development of AKI. 
In this study, we found that plasma and urine NGAL measured at the time of admission 
were good predictors of AKI. The test performance of both plasma and urine NGAL 
increased as the severity of the functional damage to the kidney’s increased; the AUC’s 
ranged from 0.77 (RIFLE R) to 0.86 (RIFLE F) for plasma NGAL and from 0.80 (RIFLE R) 
to 0.88 (RIFLE F) for urine NGAL.
Previous studies in pediatric ICU patients with sepsis and septic shock [14] and in a 
group of adult critically ill patients [17] have studied the predictive accuracy of  plasma 
and urine NGAL reporting AUC’s of 0.68 and 0.64 for sustained AKI. Both Zappitelli et al. 
(pediatric population) and Cruz et al. (adult population) observed AUC’s for prediction of 
RIFLE R or worse AKI by NGAL that were comparable to those observed in the present 
study[16, 19].  Constantin and Nickolas et al. reported very high AUC’s for the ability of 
plasma and urine NGAL to predict AKI in critically ill adult and emergency department 
patients (0.92 and 0.95 respectively) [13, 18]. Several explanations exist for the 
observed variability of NGAL’s test performance in these studies, in which the timing of 
renal insult was not strictly identified.
First, in the current study NGAL measurement was performed immediately following ICU 
admission and patients were monitored for the occurrence of AKI for the next 7 days. 
The timing of NGAL measurement in the previous studies mentioned above ranged from 
48 hours after the initiation of mechanical ventilation (up to 3 days after admission) 
to within 24 hours of ICU admission to the first possible moment upon ICU admission. 
With the rapid changes in plasma and urine NGAL concentrations, the slow changes in 
SCr concentrations, the reversibility of the early phases in the continuum of AKI and 
the effects of intensive resuscitation in the golden hours after ICU admittance, timing 
of measurement will have effects on the NGAL concentrations measured in relation to 
the changes in SCr [31]. Therefore the time at which NGAL levels are measured clearly 
influences their test performance.
Second, the number of AKI patients in a given study as well as their RIFLE class 
distribution also influences test results [32]. Due to the large sample size in this study 
and the fairly equal patient distribution between RIFLE categories, we were able to 
analyse the ability of NGAL to predict more severe AKI endpoints, such as RIFLE F. 
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In contrast, Wheeler et al. used very unusual criteria for AKI, making it impossible to 
compare their results with those of other studies. The AKI cohort in the study performed 
by Siew et al. comprised of patients with less severe stages of AKI (median urine 
NGAL 127 ng/ml IQR: 32- 623 and median SCr 1.5 mg/dL IQR: 1.0-2.2 at enrollment) 
resulting in low performance characteristics of NGAL (AUC= 0.71 95% CI 0.63-0.78). 
Nickolas et al. reported that NGAL was an excellent predictor of AKI (AUC= 0.95 95% CI: 
0.88-1.0) in an emergency department setting. However, the mean SCr and fractional 
sodium excretion of this entire AKI subgroup at the time of study inclusion were 5.6 
mg/dL (SD=5.5) and 6.9% (SD 9.1) respectively, indicating that severe loss of renal 
function had already occurred in the majority of these patients. Accordingly, test results 
generated in patients with established AKI should not be used for the comparison with 
those in a cohort of developing AKI.
Third, AKI and its severity defined by RIFLE are dependent upon how baseline SCr values 
are determined and will contribute to different outcomes between studies. In our study 
the first available SCr value was used as a surrogate baseline when a patient’s historical 
data were not available. This undoubtedly has resulted in an underestimation of attained 
RIFLE stage in some of these patients. Furthermore, with the artificial definition of AKI 
using three set severity stages the issue of timing may simply be definitional. 
This study adds to the current literature as it showed that NGAL significantly improves 
the diagnostic accuracy for severe AKI adding it to MDRD eGFR calculated at ICU 
admission, even in patients having an apparently normal eGFR at admission. Especially 
in these patients this could be of value as their AKI is not yet reflected in an increase 
in SCr. ICU patients are typically diagnosed with AKI several days after the onset of 
their illness or injury, resulting in a delay in the discontinuation or dose adjustment of 
nephrotoxic medications or continued use of procedures that could cause further renal 
damage. Whether NGAL levels have the potential to influence clinical decision making 
in the ICU should be the topic for further randomized studies that should be performed 
before using NGAL measurements in clinical practice.
These studies may include applying more intensive resuscitation, avoiding nephrotoxic 
drugs or implementation of a more timely initiation of RRT in patients with elevated 
NGAL levels [33]. Additionally, recent animal studies examining interventions to reverse 
AKI have been promising, implying that it may be possible to reverse AKI in humans if 
it is treated early [29, 34-39]. Secondly, this study adds to current knowledge since we 
defined a most efficient clinical model in the prediction of AKI using available data at the 
time of ICU admission improving the predictive accuracy for RIFLE F significantly with 
NGAL above eGFR and clinical predictors. The predictive accuracy of eGFR on its own 
was roughly comparable to that of plasma or urine NGAL. However, we should take into 
account that SCr is used to define the endpoint RIFLE F and is likewise used to calculate 
eGFR which is incorporation bias. Therefore it is somewhat biased to compare NGAL’s 
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performance with the ability of SCr to predict itself. Furthermore, in this study, the 
point of first AKI was satisfied in many patients at the time of ICU admission (58.5%). 
As such, it is to be expected that in many of the AKI cases, SCr would already be 
elevated at the time of admission. AKI that was present at the time of ICU admission 
was determined by retrospective collection of baseline SCr values from the patient 
records prior to admission.  However in clinical practice, a prior baseline SCr is more 
often not available at ICU admission and as such it is not possible to correctly determine 
the endpoint of AKI as compared to CKD. Furthermore, we should also take into account 
that NGAL is a direct injury marker that is unfortunately compared to a “gold standard” 
AKI diagnosis that is based on a functional marker (SCr) which has major imperfections 
on its own [40]. In this context it is indispensable to emphasize the importance of 
(injury) biomarker combinations to achieve more accurate predictions irrespective of 
SCr. 
Thirdly, we showed that temporal changes in NGAL measurements do not provide 
additional information for the prediction of RIFLE F. And finally, we found that septic 
patients without AKI had markedly increased urine NGAL concentrations, whereas 
there were no significant differences between groups with regard to the plasma NGAL 
values. A possible explanation for our results lies in the two-compartment model theory 
of NGAL (which applies to an animal model under relatively normal conditions) [27] 
as well as the fact that AKI is an inflammatory disease [41].  In patients with AKI, 
Human Toll-like receptor 2 (TLR2) stimulates tubular epithelial apoptosis [42] and 
NGAL expression [43]. Bacterial pathogens produce lipoproteins and activate cytokine 
networks by inducing the expression of multiple proinflammatory genes. Lipoproteins 
also have strong affinity for TLRs that trigger an innate immune response. Therefore it 
could be postulated that these circulating ligands that are linked to tubular epithelial TLR 
activation are responsible for the increased urine NGAL concentrations that we observed 
in patients who had sepsis but showed no increases in their SCr levels [44]. However, 
a very recent study in patients with sepsis, septic shock and systemic inflammatory 
response syndrome has reported contradictory findings [45]. A possible explanation 
for this difference is the variability of the subject inclusion time (up to 48 hours after 
ICU admission). Intensive resuscitation and the administration of antibiotics may have 
already occurred before study inclusion, therefore most likely inducing rapid changes of 
urine NGAL values.
In conclusion, the present study shows that both plasma and urine NGAL levels at ICU 
admission are good predictors of severe AKI and significantly add to the prediction of 
AKI using eGFR and to a model with clinical parameters.  Because the study population 
reflects a mixed group of diagnoses that are present in most ICU’s these findings could 
have major clinical implications regarding optimization of therapy in patients at risk for 
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AKI. Our findings could also facilitate studies of the effectiveness of early therapeutic 
and supportive interventions in patients with established AKI.
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ODS-1 Patients and Methods
Laboratory sample processing
Following admission, plasma and urine samples were collected (T=0) and thereafter at 
4, 8, 24, 36, 48, 60 and 72 hours. Missing admission (T=0) samples were replaced by 
first draw values at either 4 or 8 hours after admission. This occurred for 40 plasma 
samples and 61 urine samples.
Arterial blood was sampled in EDTA tubes from an arterial line and freshly voided urine 
was collected from an indwelling catheter. Both blood and urine samples were sent 
immediately to the hospital’s general laboratory and centrifuged at 3,000 rpm at 4°C for 
10 minutes with a relative centrifugal force of 1700-g. The supernatants were aliquotted 
equally into 3 cryovials and stored at -80°C. After study completion all samples were 
shipped by air transportation on dry ice to San Diego.
NGAL quantification with Triage® point-of-care immunoassay
Plasma NGAL levels were measured with the Triage® NGAL Test point-of-care 
fluorescence immunoassay on a Triage MeterPlus (Biosite Inc, San Diego USA) using a 
commercially available NGAL cartridge. The assay device is a single-use plastic cartridge 
that contains an NGAL-specific monoclonal antibody conjugated to a fluorescent 
nanoparticle, NGAL antigen immobilized on a solid phase, and stabilizers. In addition, 
the device was engineered with integrated control features including positive and 
negative control immunoassays. After the device containing the sample is inserted into 
the Triage® MeterPlus, quantitative measurements of NGAL concentration are displayed 
on the meter’s screen within 15 minutes. The devices used in this investigation reported 
plasma NGAL concentrations between 46 ng/ml and 1300 ng/ml. The device was able to 
measure the NGAL concentrations of almost all (89.7%) samples. However, 7.9% of the 
T=0 samples had NGAL concentrations that were below the lower limit of the detection 
range and 2.4% had concentrations above the upper limit of the detection range. The 
assay variability for plasma NGAL was 15.8%. Urinary NGAL levels were measured using 
a non-commercial Triage® immunoassay cartridge with a sandwich format immunoassay 
in order to provide an appropriate detection range for urine samples. Before application 
to the cartridge, the urine samples that had NGAL concentrations exceeding the assay’s 
upper limit of detection were diluted with an equal volume of 200 mM BES buffer, pH 
7.2. The effective concentration range of the urine NGAL assay was 2.6 ng/ml to 4100 
ng/ml; none of the T=0 urine samples had NGAL concentrations that were below the 
lower limit of detection and 8.5% of the T=0 samples had NGAL concentrations that 
were above the upper limit of detection. The assay variability for urine NGAL was 13.9%. 
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ODS-2 Triage® NGAL Test point-of-care standard curves 
ODS-3 MDRD formula
The estimated glomerular filtration rate (eGFR) was calculated for each patient at ICU 
admission using the Modification of Diet in Renal Disease Study Equation (MDRD) [1]. 
MDRD Formula: eGFR= 186 * (sCr in µg/L * 0.0113) ^ (-1.154) * (Age in years) ^ 
(-0.203). The result is multiplied by 0.742 if the patient is female, assuming ethnicity 
as non-Black.
ODS-2: The Triage® NGAL Test point-of-care fluorescence immunoassay standard curves for plasma (Fig. E1) 
and urine (Fig. E2) samples. The curves plot NGAL concentrations vs. the absorbance response (AU). The dots 
represent the integrated fluorescence signal averaged over 10 individual devices for a series of known NGAL 
calibration samples.
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ODS-5 Progression of NGAL concentrations over time after ICU admission
ODS-5: The progression of plasma (E1) and urine (E2) NGAL concentrations (ng/ml) over time are stratified by 
RIFLE classification and plotted against time.

Comment
Limits of Neutrophil gelatinase 
associated Lipocalin at intensive care 
admission for prediction of acute 
kidney injury. 
Hilde RH de Geus and Jan Bakker
Am J Respir Crit Care Med. 2011 July:1: 184(1):143-143
74 Comment
We would like to thank both Dr. Glassford et al and Dr. Darmon et al for their insightful and 
complimentary letters on our article [1]. We agree with Dr. Glassford’s comment that the 
use of the current insights in different forms of urinary Neutrophil Gelatinase associated 
Lipocalin (NGAL) could have contributed to the interpretation of the increased NGAL 
levels we observed in non-Acute Kidney Injury (AKI) patients with sepsis. Unfortunately, 
at the time of this study, this differentiation was not available.  Furthermore, we agree 
that measuring NGAL routinely in every ICU patient at ICU admission might not be cost 
effective. However, in a recent study [2] we demonstrated that the average daily costs 
for patients requiring renal replacement therapy (RRT) is 36% higher compared to those 
of an “average” ICU patient without RRT. Therefore, early detection and prevention of 
progressive renal failure requiring RRT in ICU patients could save a significant amount 
of resources. In this context, the cost-effectiveness of routinely measuring NGAL in 
all patients at the time of ICU admission (single NGAL test costs: $10) is therefore 
highly dependent on the availability of successful therapies to prevent deterioration of 
renal function to RRT dependency. We believe at this moment the challenge remains 
to further improve the diagnostic tools for AKI using multivariable models combining 
clinical and biomarker data to reach more predictive precision. This may include an 
accurate definition of patients with increased a priori likelihood of developing AKI. The 
described multivariable clinical model in our study was a first attempt. 
Regarding Dr. Damon’s comments, we would like to point out that the mentioned more 
timely initiation of RRT in the discussion section guided by biomarker levels should 
be read in a hypothetical framework and is certainly not a conclusion based on the 
presented data. However, as Lameire et al [3] state in their review: “The best timing 
for dialysis also remains unclear. Early initiation might be associated with improved 
survival, but the discussion is blurred by the lack of a robust marker of renal function.” 
Our study explored whether NGAL would be a sufficient biomarker to solve this problem. 
We agree that in that sense further stratification irrespective of the RIFLE (Risk-Injury-
Failure) classification should be further explored, such as the suggested transient vs. 
sustained AKI.  We acknowledge that plasma NGAL’s performance might be influenced 
by several confounders in an adult ICU population. In fact that was exactly the rationale 
to initiate this study. Accordingly, we emphasized that NGAL is comparable to estimated 
Glomerular Filtration Rate (eGFR), but has important significant additional value 
when used in a model including eGFR and other clinical parameters. Furthermore, in 
downsizing the patient population to patients with a seemingly normal eGFR, we clearly 
showed that in these patients, when serum creatinine (SCr) is not useful, NGAL does 
have important predictive value. 
Finally, the suggestion of Dr. Darmon et al to use the serum creatinine value after 
recovery of the acute disease as the presumed steady state baseline value is incorrect in 
our opinion for several reasons. First, patients treated for severe illness in the intensive 
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care undoubtedly loose a large percentage of their muscle mass due to the catabolic 
state and will therefore have a different new absolute baseline value when compared 
to the state before admission. Because the RIFLE/AKIN scoring systems are based 
on relative changes in absolute SCr values, this will result in inaccurate stratification. 
Secondly, complete renal recovery after an episode of severe AKI is never a guarantee. 
Furthermore, it is commonly known that many of these patients will reach a new lower 
steady state renal function; therefore, it is inappropriate to use this value as the pre ICU 
baseline value for RIFLE/AKIN stage determination. 
References 
 1. de Geus HR, Bakker J, Lesaffre EM, et al.: Neutrophil Gelatinase-associated Lipocalin at ICU Admission 
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Abstract
Background: First to evaluate the ability of NGAL and Cystatin-C (CyC) in plasma and 
urine to discriminate between sustained, transient and no-AKI. And second, to evaluate 
their predictive performance for sustained AKI in adult ICU patients.
Methods: Prospective cohort study of 700 patients. Sample collection was performed 
over 8 time points starting at admission. 
Results: After exclusion 510 patients remained for the analysis. All biomarkers showed 
significant differentiation between sustained and no-AKI at all time points (p≤0.0002) 
except for urine CyC (uCyC) at admission (p=0.06). Urine NGAL was the only 
biomarker significantly differentiating sustained from transient AKI at ICU admission 
(p=0.02). Individually, uNGAL performed better than the other biomarkers (AUC=0.80, 
95%CI=0.72-0.88) for the prediction of sustained AKI. The combination with plasma 
NGAL (pNGAL) showed a non-significant improvement (AUC=0.83, 95%CI=0.75-0.91). 
The combination of individual markers with a model of clinical characteristics (MDRD 
eGFR, HCO3
- and Sepsis) didn’t improve its performance significantly. However the 
integrated discrimination improvement (IDI) showed significant improvement when 
uNGAL was added (p=0.04). 
Conclusions: Urine NGAL measured at ICU admission differentiates patients with 
sustained AKI from transient or no-AKI patients. Combining biomarkers such as pNGAL, 
uNGAL and pCyC with clinical characteristics adds some value to the predictive model.
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Introduction
Acute kidney injury (AKI) is common in adult hospitalized patients and associated with 
significant morbidity and mortality (up to 50%) [1-3].  AKI in critically ill patients is rarely 
an isolated event but usually more often part of a more multisystemic immunological 
condition contributing to remote organ dysfunction. 
However, several large cohort studies have established a strong independent relationship 
between the severity of AKI and its associated mortality. Moreover, even small changes 
in kidney function and periods of transient azotemia have considerable impact on 
outcome [4]. In order to initiate timely therapies, it seems essential to discriminate 
patients with high risk for sustained AKI from patients with lower risk. Unfortunately, 
at the moment, specific therapies for AKI are lacking even though experimental animal 
data show promising possibilities. One major setback is that these new agents show 
promise only in the early reversible stages of AKI [5]. Therefore it is essential to possess 
early and accurate detection tools for sustained AKI. 
The rise in levels of serum creatinine (SCr) is still used for the diagnosis of AKI; 
consequently it is the basis of the AKI definitions such as the RIFLE criteria. However, 
it has a poor predictive value for AKI in the early stage of renal injury.  In recent years, 
a number of novel biomarkers have been studied for their potential to detect AKI in its 
early stage [6]. 
Neutrophil Gelatinase-associated Lipocalin (NGAL) is a 25-kDa protein combined 
with a siderophore, produced by epithelial tissues throughout the human body. It is 
involved in nephrogenesis, induction of nephritic structures from mesenchymal stroma 
cells, protection against ischemic tubular damage and in iron transportation [7-10]. 
Plasma NGAL (pNGAL) is under normal conditions excreted by glomerular filtration and 
undergoes complete proximal tubular reabsorption. Urine NGAL (uNGAL) is expressed in 
the distal tubular segments where it is part of bacterial defense mechanisms. 
Cystatin-C (CyC) is a 13 kDa nonglycosylated cysteine protease inhibitor produced by 
all nucleated human cells in a constant rate unaffected by muscle mass. Plasma CyC 
(pCyC) is also excreted by glomerular filtration and has a similar catabolic pathway as 
pNGAL; therefore it is not normally found in urine in significant amounts. Some evidence 
suggests that pCyC is a superior functional biomarker compared to SCr especially to 
detect acute changes in estimated glomerular filtration rate (eGFR) [11, 12]. 
Several recent clinical studies have reported encouraging predictive properties  of NGAL 
and CyC for AKI development [12-20].  Despite the reasonable individual biomarker 
performances it is recognized that perhaps biomarker combinations or combined models 
with clinical parameters might provide additional accuracy to successfully guide clinical 
decision making [16].
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The purpose of this study was to evaluate the discriminative properties of pNGAL, uNGAL, 
pCyC and uCyC between various AKI disease states and the biomarkers’ performance on 
the prediction of developing sustained AKI.  
Materials and methods
Study population
Between September 1, 2007, and April 1, 2008, all consecutive admitted patients to the 
adult ICU of the Erasmus MC University Medical Center In Rotterdam, the Netherlands, 
(which treats general surgical, trauma, medical, neurological and neurosurgical 
patients, but not cardiac surgery patients) were considered for participation (n=700). 
Exclusion criteria were age under 18, re-admission during the study period (only the first 
admission records were included), refusal of informed consent, nephrectomy, chronic 
kidney disease (CKD stages 3, 4 and 5 based on eGFR criteria calculated with the 
baseline SCr values) and renal transplantation. Written informed consent was obtained 
from all participants or their legal representative with a deferred consent policy [21]. 
The study was approved by the institutional review board.
Study protocol
At ICU admission (T=0) and at 7 time points thereafter (T=4, 8, 24, 36, 48, 60, 72 hrs) 
plasma and urine sampling was performed using an intra-arterial line and a urine catheter 
for spot urine. The samples were immediately processed in the hospital’s laboratory and 
the supernatants were stored at -80°C. NGAL and CyC concentrations were measured 
by Biosite Inc in San Diego using the Triage® immunoassay. SCr values were measured 
in the hospital’s clinical chemical laboratory (using the enzymatic kit produced by Roche 
which is traceable to a reference method based on isotope dilution-mass spectrometry) 
at the time of admission and thereafter daily at 6:00 am. The estimated glomerular 
filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease 
Study Equation (MDRD) [22] and baseline SCr was defined as the patient’s steady 
state level four weeks prior to ICU admission. If not available, the admission value 
was used as the baseline. AKI was defined according to the RIFLE (Risk-Injury-Failure) 
classification [23]. The RIFLE classification is based on the rise in SCr compared to a 
baseline value. Risk represents a 1.5-2 times increase, Injury a 2-3 times increase and 
Failure a more than 3 times increase. Sustained AKI was defined as any AKI occurring 
and persisting for more than 24 hours after admission. Transient AKI was defined as 
reaching AKI only once with normalizing SCr levels within 24 hours. Other recorded 
variables included age, gender, body mass index (BMI), bicarbonate levels (HCO3
-), 
blood urea nitrogen content (BUN), white blood cell count (WBC), Acute Physiology and 
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Chronic Health Evaluation score (APACHE II), sequential organ failure assessment score 
(SOFA), cumulative urine output (UP), initiation of RRT, patient discharge diagnosis, 
length of ICU stay, ICU mortality and hospital mortality. 
NGAL measurements
The Triage® point-of-care immunoassay was used to determine plasma and urine NGAL 
concentrations. The detection limit for the pNGAL assay was 46 ng/ml to 1300 ng/
ml and 2.6 ng/ml to 4100 ng/ml for uNGAL.  Urine samples that had concentrations 
exceeding the assay’s upper limit were diluted with an equal volume of 0.2 M BES buffer 
before application to the cartridge.  The pNGAL assay on this platform has been shown 
to correlate strongly with other methods of pNGAL detection [24].
Cystatin-C measurements
The Triage® Test point-of-care immunoassay was used to measure CYC in both plasma 
and urine on a research based cartridge. Plasma samples were measured neat and 
calibrated with a cystatin C-spiked plasma pool.  The urine assay was calibrated with a 
urine pool diluted 1:1 with a buffer (0.2M BES), which was necessary to dilute the urine 
samples for appropriate detection. The plasma CyC assay’s performance was validated 
against the commercially available Dade method. 
Data analysis
Patients were classified into three groups: no-AKI, transient AKI and sustained AKI. 
Demographics and clinical outcomes were summarized and compared among groups. 
For continuous variables, median and inter-quartile ranges (IQR) were reported and 
Kruskal-Wallis test was used to test for group differences. For categorical variables, 
frequencies and proportions were reported and Fisher’s exact test was used to test 
for group differences. Considering the highly skewed values in some biomarker 
measurements, medians and IQRs were presented for biomarker levels measured at 
each time point to show the temporal trend of biomarker levels over time. At each 
time point, the medians were compared between groups (no AKI, transient AKI and 
sustained AKI) for all patients and between RIFLE categories for sustained AKI patients 
using the rank transformation approach. Tukey-Kramer multiple comparison adjustment 
was utilized to adjust for the three pairs of comparisons at each time point, and adjusted 
p-values were reported where multiple comparisons were involved.To compare the 
discrimination of sustained AKI vs. no-AKI and sustained AKI vs. transient AKI using 
the four biomarkers at admission to ICU, receiver operating characteristic (ROC) curves 
were generated and the areas under the curves (AUC) were compared to select the best 
performing biomarker. The performance of the combination uNGAL and the others was 
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also investigated to show if there was any improvement in the discrimination of AKI 
patients. 
Multivariable logistic regression analyses were conducted to assess predictors of 
sustained AKI and the performance of the predictive models while combining biomarkers 
with clinical factors. The clinical factors considered included MDRD eGFR at admission, 
diagnosis of sepsis and the following laboratory measures measured at admission: 
HCO3⁻, BUN, white blood cell count (WBC). A parsimonious clinical model was first 
determined based on stepwise backward elimination. Each of the four biomarkers 
was added individually to the parsimonious clinical model and the performance of the 
predictive models was evaluated using Akaike Information Criterion (AIC), Hosmer-
Lemeshow test of goodness of fit, AUC, Net Reclassification Improvement (NRI) and 
Integrated Discrimination Improvement (IDI). Statistical analysis was performed using 
SAS version 9.2 (SAS Institute, Cary, NC) and R package Hmisc (http://CRAN.R-project.
org/package=Hmisc) was used to calculate NRI and IDI.  A significance level of 0.05 
was used for all analyses.
Role of the Funding Source
Biosite incorporated provided biomarker measurements. They had no role in study 
design, conduct, data-analysis and reporting. Besides biomarker measurements no 
additional funding was provided.
Results
Patients
Seven hundred patients were initially consented to be enrolled in the study. After 
adopting the exclusion criteria, 98 patients were excluded. Another 92 patients were 
excluded because of established AKI before or at ICU admission leaving 510 patients 
included in the analysis.  Patients’ baseline and clinical characteristics are presented 
in Table 1. Patients with sustained AKI had a significant higher baseline SCr, with 
correspondingly lower estimated glomerular filtration rate by the Modification of Diet in 
Renal Disease Study Equation (MDRD eGFR), lower serum bicarbonate levels (HCO3- ), 
higher blood urea nitrogen content (BUN), higher pNGAL, uNGAL and pCyC values at 
admission, higher APACHE II and SOFA scores, lower 24-hour urine production (UP), 
higher 24-hour cumulative fluid balance (FB-24) and significantly increased ICU and 
hospital mortality.
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Biomarker performance for differentiation between no-AKI, transient AKI and 
sustained AKI
The temporal trend of each biomarker and SCr for patients grouped into no AKI, 
transient AKI and sustained AKI is shown in Fig.1A-E. All four biomarkers as well as 
SCr showed significant differentiation between sustained AKI and no AKI at all time 
points (all p≤0.0002) except for uCyC at the time of ICU admission (p=0.06) (Table 
2).  The timing of first significant differentiation between sustained AKI and transient 
AKI differed substantially by biomarker. Urine NGAL was the only biomarker to show 
significant differentiation of sustained from transient AKI at admission and at all time 
points thereafter (all p≤0.02); uCyC significantly differed at T=4 (p=0.03) and T=8 hours 
(p=0.04); pCyC first showed significant differences at 24 hours (p=0.005); pNGAL did not 
differ until 36 hours (p=0.0002) (Table 2).  Differentiation between transient and no AKI 
was more variable, with pCyC differing only at 4 hours (p=0.02); pNGAL differentiating 
only at 4 and 8 hours (p≤ 0.009); SCr differing at 24, 48 and 72 hours (p≤ 0.0008) which 
is as expected by definition; and uNGAL and uCyC unable to distinguish no AKI from 
transient AKI at any time point at or after ICU admission (Table 2).
Biomarker performance for differentiation of AKI severity
Patients with sustained AKI were divided into three groups based on their RIFLE 
categories (R=Risk 1.5-2.0 times increase in baseline SCr, I=Injury 2.0-3.0 times and 
F=Failure more than 3 times) (n=47). The temporal trends of each biomarker and 
SCr are shown in Fig. 2A-E. Neither pCyC nor uCyC showed significant differentiation 
among the RIFLE categories at any time. Plasma NGAL did not significantly differentiate 
between F and I or between I and R; but started to show differentiation between F 
and R at 8 hours after ICU admission (p=0.01). The differentiation of RIFLE categories 
using uNGAL was similar to pNGAL. Urine NGAL only showed significant differentiation 
between F and R at 4 hours (p=0.04), 24 hours (p=0.02) and 72 hours (p=0.049), 
and between I and R at 24 hours (p=0.03). At ICU admission and 24 hours after ICU 
admission, SCr did not show significant differentiation among RIFLE categories, and 
only started to differentiate F vs. R at 48 hours (p=0.0004) and F vs. I at 72 hours 
(p=0.03) (Table 2).
Performance of biomarkers measured at admission in prediction of sustained 
AKI 
To compare the performance of each individual biomarker on the prediction of AKI 
and to investigate the performance of combinations of biomarkers, subjects who had 
missing values in one or more biomarkers at the time of admission were excluded for 
ROC curve analysis. Four hundred and seventeen patients were included to investigate 
the discrimination of sustained AKI (RIFLE R and above for more then 24 hours, 
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Figure 1: The changes of the individual biomarker concentrations over time after ICU admission summarized 
by Sustained, Transient and no AKI; for  SCr (A) and the four biomarkers pNGAL (B), uNGAL (C), pCyC (D) and 
uCyC(E).  Median and interquartile range (IQR) presented on a Log10 scale. 
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Figure 2: The changes of the individual biomarker concentrations over time after ICU admission summarized 
by RIFLE stages Risk (=R), Injury (=I) and Failure (=F);  for  SCr (A), and the four bioamarkers pNGAL (B), 
uNGAL (C), pCyC (D) and uCyC (E). Median and interquartile range (IQR) presented on a Log10 scale. 
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Figure 3 A: ROC curves and corresponding AUC’s for the prediction of sustained AKI (n=37) vs. no-AKI 
(n=375) at ICU admission pNGAL, uNGAL, pCyC and uCyC. B: ROC curves and corresponding AUC’s for the 
prediction of sustained (n=37) vs. transient AKI (17) at ICU admission pNGAL, uNGAL, pCyC and uCyC. C: ROC 
curves and corresponding AUC’s for the prediction of Sustained (n=37) vs. no-AKI (n=375) at ICU admission 
for uNGAL in combination with SCr, pNGAL, pCyC and uCyC
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n=37) vs. no AKI (n=380) using different biomarkers. All studied biomarkers (pNGAL, 
uNGAL, pCyC and uCyC) were significant predictors of sustained AKI (p< 0.005). 
Urine NGAL showed the best discrimination of sustained AKI vs. no-AKI with an AUC of 
0.80 (95%CI=0.72-0.88) compared to pNGAL (AUC=0.76, 95% CI=0.67-0.85), pCyC 
(AUC=0.71, 95%CI=0.62-0.80) and uCyC (AUC=0.61, 95%CI=0.52-0.70) (Fig. 3A). 
There was no significant difference in AUC between uNGAL and pNGAL, or between 
uNGAL and pCyC. But uNGAL had significantly higher AUC compared to uCyC (p< 
0.0001). As to the discrimination of sustained AKI (n=37) vs. transient AKI (n=17), 
uNGAL was the only marker which showed significance with an AUC of 0.77 (95% CI 
=0.64-0.90) (Fig. 3B). 
Biomarker combinations for prediction of sustained AKI measured at 
admission
Combining uNGAL with one of the other three biomarkers did improve the AUC’s for the 
discrimination of sustained vs no-AKI; however the improvements were not statistically 
significant. The best combination was uNGAL and pNGAL, improving the AUC to 0.83 
(95% CI = 0.75-0.91) from 0.80 with uNGAL alone (Fig. 3C). There is no improvement 
in combining biomarkers for the discrimination between sustained and transient AKI.
Multivariable logistic regression analysis for prediction of sustained AKI
To have a fair comparison between the biomarkers patients with missing values in any of 
the five clinical variables (MDRD eGFR, HCO3-, BUN, WBC, Sepsis) and the four biomarkers 
at the time of ICU admission were excluded from the multivariable logistic regression 
analysis. This resulted in a total of 389 patients (33 sustained AKI vs 356 others). After 
a stepwise backward elimination, MDRD eGFR, HCO3
- and diagnosis of sepsis remained 
in the parsimonious clinical model as independent predictors of sustained AKI (p=0.002, 
p=0.045 and p=0.0001 respectively). The additional contribution of biomarkers to the 
prediction of sustained AKI was evaluated by adding each biomarker individually to the 
parsimonious clinical model (Table 3).  Urinary NGAL and pCyC showed to be significant 
predictors of sustained AKI even with the existence of the three clinical factors. Plasma 
NGAL was marginally significant (p=0.052) and uCyC was not significant (p=0.76) after 
they were added to the parsimonious clinical model. The model with uNGAL showed the 
best goodness of fit based on the comparison of AIC (>7 decrease in the magnitude 
of AIC from the clinical model) and Hosmer-Lemeshow test (p=0.21). There was 
minor improvement in AUC (0.018 – 0.024) when combining a biomarker with the 
parsimonious clinical model, but the improvement was not statistically significant except 
for pNGAL (p=0.03). Additional evaluation of the performance of the combined models 
was conducted by calculating NRI and IDI for each combined model vs the parsimonious 
clinical model. Since no standard scale is available for the choice of classification risk 
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levels, NRI was calculated based on the increase or decrease of predicted individual 
probability of developing sustained AKI. Significance was shown in NRI for models 
containing uNGAL (NRI=0.38, p=0.04) or pNGAL (NRI=0.42, p=0.02). Another index 
for the evaluation of the performance of a predictive model, IDI, showed significance 
improvement for the model containing uNGAL (IDI=0.06, p=0.04). Considering the 
components of IDI, the combined model with uNGAL showed significant improvement in 
classification specificity (p= 0.04). 
Discussion
This study is the first to our knowledge to demonstrate the utility of urinary NGAL as 
a biomarker that could be used upon admission to the ICU to distinguish critically ill 
adults who are likely to develop sustained versus transient AKI from those at minimal 
risk of AKI.  Such an early clinical determination may allow for the alteration of clinical 
care toward prevention and early treatment of AKI, prior to the rise in serum creatinine 
typically used to diagnose AKI.  However, this study also suggests that NGAL and 
cystatin-C, either alone or in combination, are not able to accurately or persistently 
discriminate AKI RIFLE severity among critically ill patients with developing AKI. 
Furthermore, although based upon small event sample size the results suggest modest 
additional value of the markers when added to a model with clinical variables. These 
negative findings are also important, as they suggest important limitations of these 
biomarkers in this critical care setting.
The cellular and molecular aspects of ischemic and septic AKI are currently being 
increasingly unraveled.  Major progress has been made in the knowledge of the underlying 
pathophysiological mechanisms and possible targets for therapeutic interventions. 
However the translation of these findings to clinical patient related practice has been 
disappointing. Different pathophysiological stages of AKI have been identified, including 
a prerenal, initiation, extension and maintenance phase. Therapy must be considered in 
the context of these different stages, because applying them in the maintenance phase 
has proven to be unsuccessful. Therefore early recognition and discrimination of the first 
stages of AKI, not yet reflected by functional impairment, is very important [5, 25]. The 
presented data show to our knowledge for the first time that that urine NGAL is able to 
provide information on the discrimination between sustained and transient AKI in the 
early clinical course of AKI development, upon admission to the ICU. Such information 
may prove useful in the early initiation of several emerging strategies, such as innate 
immune system modulators, growth factors, regulatory T-cells, cytoprotective agents 
such as activated protein- C, statins and erythropoietin.  In addition, there are issues 
we would potentially address differently in current practice in patients destined for 
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sustained AKI if we could discriminate them from patients with self limiting renal injury. 
For example, we would attempt a more intense regime of “golden hour resuscitation” 
with intensive hemodynamic monitoring of macro- and micro circulation, we would
avoid nephrotoxic agents and most importantly we would attempt more timely initiation 
of RRT to at least control cumulative fluid balances and toxic uremic conditions that are 
clearly correlated with survival and ventilator free days  [26-31].  
Several studies report promising  test results for NGAL (AUC’s ranging from 0.71-0.92 ) 
[13-16, 32] and CyC (AUC’s ranging from  0.50- 0.78) [18, 19, 33-35] for AKI prediction 
in adult critically ill patients. However, the AUC results are not very consistent and highly 
depended on the selected patient cohort (general ICU patients vs. cardio pulmonary 
bypass surgery patients vs. septic patients etc), and on the inclusion or exclusion of 
pre-existing CKD or pre-existing AKI. Therefore newer trends in biomarker research 
have been directed towards use of biomarker models that include clinical parameters 
to improve the test accuracy for early detection of AKI  in well defined clean cohorts 
[36-38]. 
The current study excluded patients with known CKD or AKI, improving the homogeneity 
of our cohort and allowing for an assessment of incident AKI only. The current study 
also describes the individual and combined performance of four different biomarkers 
(pNGAL, uNGAL, pCyC and uCyC) allowing for their direct comparison.  In this analysis 
the prediction of sustained AKI was not significantly different when considering the ROC 
AUC’s between pNGAL, uNGAL, pCyC and uCyC. This may be partly explained by the 
reduction in sample size using patients with developing AKI only. Adding the individual 
biomarkers to a model with clinical characteristics the improvement of the combined 
model with uNGAL, pNGAL and pCyC was comparable and therefore any potential 
superiority of a biomarker could not be demonstrated, except for uCyC which was not a 
significant predictor in the multivariable model. 
Several issues have to be considered concerning potential limitations of this current 
work: First, defining a patient’s baseline SCr is a problem in emergency medicine. Not 
uncommonly these variables are not available due to the absence of a patient’s medical 
history in the hospital charts. Using the first available SCr value, such as we did, might 
therefore be a reason for some underestimation of AKI severity and might contribute to 
biomarker test non-specificity. However, the procedures we employed in this study are 
consistent with the clinical determination of AKI. Furthermore, these described results 
have to be considered in a research based setting and may not reflect entirely common 
clinical practice. For the purpose of the analysis this cohort was reduced to patients 
with developing AKI only and thus patients having reached a 50% or more increase in 
SCr before or at admission were excluded. This is only possible with the availability of 
the historical SCr baseline values. It is very common however that in clinical practice 
the information on a patient’s true baseline SCr value is not immediately available and 
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thus the clinical applicability of the differentiation between transient and sustained AKI 
remains to be proven as having additional value.  
Second, we have to take into account that new biomarkers such as NGAL (injury 
marker) and CyC (functional marker) are tested against a gold standard that has 
huge imperfections on its own. Therefore we should keep in mind that the lack of 
a biomarker’s sensitivity and specificity in the present approach may actually reflect 
SCr’s imperfections [6]. Third, the biomarker urine values are not corrected for urine 
creatinine concentrations; however this is defendable since there is evidence that it is 
not likely to have a considerable impact on overall test performance [39]. Fourth, in 
this study all patients with chronic kidney disease (CKD) were excluded making the 
results possibly less applicable to the general adult intensive care population where we 
observe increasing numbers of patients entering the ICU with CKD. Finally, plasma and 
urine NGAL were the only inducible damage markers used in this panel. The additional 
contribution of uCyC in this model was disappointing. Our findings are in contrast with 
the conclusions of the work of Koyner et al. [34] and several others stating that CyC 
may be an improved estimator of GFR particularly in patients with very subtle changes 
in kidney function and injury [18, 19, 38, 40]. Recent data demonstrate that in the 
absence of CKD, serum and urine CyC may be associated with inflammatory biomarkers 
in an elderly ambulatory population and sepsis in general ICU patients [41, 42]. A 
possible hypothesis is that CyC itself may be a regulator of inflammation, which might be 
of influence in adult critically ill patients being known for their pro-inflammatory state. 
Accordingly, this population receives frequent corticosteroid treatment in subgroups such 
as sepsis and liver transplant patients and suffers from thyroid dysfunction syndromes. 
Using other particular damage markers such as Kidney Injury Molecule-1 (KIM-1) 
[43], Interleukin-18 (IL-18) [44], Netrin-1 [45, 46] or liver fatty acid binding proteins 
(L-FABP) [47] might potentially have a significant additional predictive contribution to 
the biomarker panel model, which should be a subject of exploration in the near future. 
In conclusion, we showed that urine NGAL accurately discriminates adult patients 
likely to develop sustained AKI from transient AKI at the time of ICU admission. In 
addition, we showed that NGAL and cystatin-C, either alone or in combination, are not 
able to accurately or persistently discriminate AKI RIFLE severity among critically ill 
patients with developing AKI. However, adding uNGAL, pNGAL and pCyC to a model with 
clinical characteristics slightly improved the discrimination of the predictive model. And 
especially, adding uNGAL to the clinical model significantly improved the performance of 
the prediction in terms of both NRI and IDI.  
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Plasma neutrophil gelatinase associated 
lipocalin similarly predicts acute kidney 
injury in sepsis and non-sepsis
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Abstract 
Plasma neutrophil gelatinase-associated lipocalin (NGAL) is released in sepsis irrespective 
of acute kidney injury (AKI). We investigated the effect of sepsis on its diagnostic value 
for AKI. In 700 ICU admissions, at 4 time-points (<24 hours) following admission, NGAL 
was measured. Six-hundred-sixty-three admissions were included in the final analysis, 
of which 80 patients had sepsis (12%). AKI occurred in 22% of the patients without 
and 66% with sepsis. NGAL levels were higher in no-AKI patients with sepsis compared 
to no-AKI patients without sepsis at all time points (p=0.03 or lower). In patients with 
AKI a similar difference was observed (p<0.001).  The area under the curve (AUC) for 
AKI was unaffected by the presence of sepsis (0.76 in sepsis vs. 0.78 in non-sepsis 
[p=0.72]), but the optimal test cut-off values were higher in the former. 
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Introduction
Acute kidney injury (AKI) is common in adult hospitalized patients and is associated with 
high morbidity and mortality (up to 50%) [1-3]. Biomarker-guided risk stratification for 
occurrence of AKI might allow timely provision of supportive and interventional care 
which in turn might influence outcome. Several biomarkers have been proposed as 
potential candidates such as neutrophil gelatinase-associated lipocalin (NGAL).
AKI is defined using a relative increase of serum creatinine (SCr) compared to a 
predefined steady state baseline value [4]. However, in clinical practice the baseline 
value is difficult to obtain or simply not available. In clinical studies, therefore, the 
baseline SCr values are frequently estimated using age, gender and bodyweight or 
the first available SCr value is applied as a surrogate “steady sate” baseline value. 
The applied definition of baseline SCr value evidently determines the occurrence of 
AKI, especially in the milder severity stages, and therefore might change the value of 
biomarkers to diagnose AKI.  
NGAL is an early predictor for AKI in specific populations such as pediatric patients after 
cardiopulmonary bypass surgery, in which onset of AKI can be specified [5]. Sepsis is 
prevalent in critical illness and the leading cause of AKI [3], and septic AKI in particular is 
characterized by distinct pathophysiology [6]. Plasma NGAL also differentiates between 
bacterial and viral infections irrespective of the presence of AKI [7-10]. Therefore, the 
distinction between septic and non-septic AKI in a heterogeneous patient cohort may 
have clinical relevance for the biomarker test characteristics.
Two studies describe the behavior of plasma NGAL in patients with sepsis and show that 
sepsis elevates NGAL levels in plasma, but it is still unclear what the precise impact is 
on the diagnostic test characteristics [11, 12].  To clarify this issue and to asses the 
effect of different SCr baseline values we evaluated the role of sepsis on the diagnostic 
test properties for AKI of plasma NGAL in a large cohort of adult critically ill patients. 
The hypothesis is that sepsis alters optimal cut off values but not the diagnostic value 
of NGAL for AKI, as compared to non-sepsis.  
Methods
Design and setting
This is a prospective single center cohort study in a 30-bed closed format university 
hospital intensive care unit (ICU) on which general surgical, trauma, medical, neurological 
and neurosurgical patients are treated (no cardiac surgery). All consecutively admitted 
adult critically ill patients between September 1 2007 and April 1 2008 were considered 
eligible. Exclusion criteria were age under 18, refusal of informed consent, a history 
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of nephrectomy, documented chronic kidney disease (CKD) (> stage 3) and renal 
transplantation. The study was approved by the institutional review board of the 
Erasmus MC University Medical Center in Rotterdam, the Netherlands. Deferred consent 
was used with written informed consent obtained from the participants or their heath 
care proxy within 48 hours after ICU admission [13]. In the case of consent refusal (n=6 
0.9%) the collected plasma specimens were appropriately destroyed. The current study 
is an extended analysis of one previously reported [14], now focusing on the effects of 
sepsis on biomarker behavior. Demographic data were recorded including severity of 
illness scores, renal characteristics and outcome parameters (Table 1).
Sample collection
At ICU admission (T=0) and at 4 time points thereafter (T=4 8 24), plasma samples 
were collected using an intra-arterial catheter. The samples were processed in the 
hospital’s laboratory and the supernatants stored at -80°C. NGAL concentrations were 
measured after study closure by Biosite Inc (Alere), San Diego, USA using the Triage® 
immunoassay. The detection limit for the plasma assay was 46 ng/ml - 1300 ng/ml. The 
assays coefficient of variation was 15.8%. SCr values were measured in the hospital’s 
clinical chemical laboratory at time of admission and daily thereafter at 6:00 am. SCr 
values were measured with the Roche enzymatic kit which is traceable to a reference 
method based on isotope dilution mass spectrometry. 
Definitions
Two definitions of baseline SCr were applied. First, the steady state level at four weeks 
to six months prior to ICU admission, when available, and second, the first available 
SCr 24 hours prior to ICU admission or on admission (available in the electronic 
supplementary material, ESM). AKI was defined using the acute kidney injury network 
(AKI) classification for changes in SCr values (AKI 0= no-AKI AKI 1= SCr increase 
>50% or an absolute SCr rise of 0.3 mg/dL [=26.5 µmol/L], AKI 2= SCr increase 
> 100% and AKI 3= SCr increase >200% compared to baseline) [4]. Sepsis on 
admission was defined according to ACCP/SCCM consensus criteria. Patients with a 
proven or suspected infection, two or more systemic inflammatory response syndromes 
(SIRS) criteria and an infection-induced organ dysfunction were classified as having 
severe sepsis. The admission and peak biomarker levels were used for diagnosis of 
AKI. The primary study endpoint was AKI (AKI stage 1 or more) within 48 hours after 
ICU admission. The Acute Physiology And Chronic Health Evaluation (APACHE) II and 
Sequential Organ Failure Assessment (SOFA) score (without renal parameters) were 
calculated from documented physiological and chronic disease variables. Other collected 
parameters were demographic data (age, gender, diagnosis), renal parameters (urine 
production (UP), cumulative fluid balance (FB), application of continuous venovenous 
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renal replacement therapy (CVVH)), inflammatory parameters (white blood cell count 
(WBC), C-reactive protein (CRP), sepsis source and cultured micro organisms) and in 
hospital mortality.  
Statistical analysis
Patients were grouped according to the presence of sepsis. Most data were non-normally 
distributed and reported as number (percentage) and median (interquartile range), 
where appropriate. Univariate analysis for continuous variables was with Mann-Whitney 
U test and for categorical variables with the χ2 test or Fisher’s exact test.  Receiver 
operating characteristic curves (ROC) were generated for the occurrence of AKI using 
the admission and peak biomarker level within first 24 hours after admission. The area 
under the curve (AUC) was expressed with the 95% confidence interval (95% CI) and 
the optimal cut off level (Youden index) was calculated with corresponding sensitivity 
and specificity. The significance level (P-value) was two tailed and 0.05 was used for all 
analyses. Exact P values are given unless <0.001. Statistical analyses were performed 
with the statistical software package SPSS version 20.0 (IBM SPSS Chicago IL USA) 
for windows and MedCalc for Windows version 9.5.0.0 (MedCalc Software Mariakerke 
Belgium).
Figure 1: Patient cohort. AKI is classified applying a baseline serum creatinine value until 6 months prior to ICU 
admission. CKD: chronic kidney disease; AKI: acute kidney injury; TX: transplantation 
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Figure 2: Plasma NGAL concentrations in patients stratified for sepsis and (severity of) AKI. AKI is classified 
applying a baseline serum creatinine value until 6 months prior to ICU admission.  NGAL: neutrophil gelatinase-
associated lipocalin; AKI: acute kidney injury. Groups are compared using Mann-Whitney-U-test: * P<0.05, ** 
P<0.001 and NS= non-significant.
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Results
Patients
The initial cohort comprised of 700 consecutive admissions. Six patients refused 
permission for participation (0.9%), 6 patients had undergone a nephrectomy (0.9%) 
and 25 patients had chronic kidney disease (CKD) stage 3 or more or with a kidney 
transplant (4%) leaving 663 admissions for the overall analysis. All readmissions during 
the study period were used in the analysis (N=56). When applying the first definition 
of AKI, using the baseline SCr value 4 weeks to 6 months prior to admission, 39 cases 
(6%) lacked a steady state baseline SCr of whom 2 developed AKI. Baseline clinical 
characteristics are depicted in Table 1. One hundred eighty one (27%) patients had AKI 
(=AKI stage 1 2 or 3) within the first 48 hours of admission. In patients without sepsis 
(N=583), 128 had AKI (22%) and in patients with sepsis 53 out of 80 (66%) (Figure 
1). Non-septic patients with AKI were more severely ill according to the APACHE II and 
non-renal SOFA scores, had a higher baseline SCr, a lower averaged urine production 
and a higher cumulative fluid balance during the first 24 hours of admission compared 
to non-septic patients without AKI. In septic patients the SOFA score was comparable 
between patients with and without AKI. The source of sepsis and the cultured micro–
organisms is described in ESM-1.
Plasma NGAL concentrations in patients with and without sepsis.
Median peak plasma NGAL concentrations were higher at all time points in patients 
with sepsis compared to patients without sepsis irrespective of the presence of AKI 
(P=0.03 in non-AKI and P<0.001 in AKI) (Figure 2). This trend persisted when AKI 
patients were sub classified into the different severity stages (AKI 1, AKI 2 and AKI 3) 
(Figure 2). Median peak NGAL concentrations were different at all time points after ICU 
admission between patients with and without AKI, both in septic and non-septic patients 
(P<0.001) (Table 2). 
Diagnosis of AKI
ROC curve analysis was performed for admission and peak plasma NGAL levels in 
patients with and without sepsis. The area under de curve (AUC) for peak values 
was unaffected by the presence of sepsis (0.78 [0.67-0.86] for sepsis [P=0.72] and 
AUC=0.76 [0.72-0.79] for non-sepsis) (P=0.72). Similar AUC’s were obtained with 
admission NGAL values. The optimal cut-off level of NGAL was higher in sepsis than in 
non-sepsis (979 vs 338 ng/ml) (Table 3A and B). 
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Alteration of baseline SCr definition
The above described analysis was also performed applying the alternate baseline SCr 
value (SCr available at ICU admission or 24 hours prior to admission) (ESM 2-7). Less 
patients classified as having AKI (N=120 patients instead of N=181) (ESM-2). Plasma 
NGAL concentrations were similarly higher in septic and non-septic patients with and 
without AKI (P<0.001) (ESM-4 and 6). Furthermore, the ROC AUC’s for diagnosis of AKI 
with admission and peak NGAL levels in septic and non-septic patients were similar to 
those generated with peak NGAL levels (ESM-5). 
Discussion
The present study confirms that sepsis enhances the production of plasma NGAL in adult 
critically ill patients irrespective of the presence of AKI. However, the diagnostic test 
accuracy for AKI is unaffected by sepsis, but optimal cut-off values are elevated. 
Two other studies report on the possible confounding role of sepsis on NGAL as a diagnostic 
tool for AKI. Martensson et al. found higher plasma NGAL levels with increasing severity 
of sepsis but found no differences between AKI and non-AKI patients (p=0.06). Our 
analysis resulted in the opposite:  plasma NGAL levels were higher in non-AKI patients 
with sepsis compared to non-sepsis patients without AKI and this pattern persisted in 
patients with (increasing severity of) AKI. A possible explanation might be the more 
severe AKI in our patients as compared to those of Martensson et al. [12]. 
Bagshaw et al. described patients with AKI with and without sepsis. Higher NGAL 
levels were detected in case of septic AKI (381 [253-585] ng/ml vs. 176 [92-269]). 
Remarkably, the NGAL levels are lower than in our cohort which again might be explained 
by a greater severity of illness in our patients [11]. 
One of the concerns in AKI related biomarker research is the primary study endpoint 
used: the change of serum creatinine over a 48 hour timeframe. The disability of SCr to 
detect minimal tubular damage is well recognized which generated the quest for earlier 
and more specific signals in plasma or urine, including NGAL. The determination of a 
baseline SCr used for the classification of AKI impacts on the study endpoint. Therefore 
we chose to apply two definitions of the baseline SCr level in order to address this 
matter. Our results show that the application of a baseline SCr closely prior to or at ICU 
admission reduces the number  of cases in the less severe stage of AKI (AKI 1) without 
having an affect on the AUC of plasma NGAL for AKI diagnosis. 
A possible limitation of this study is that patients with sepsis had more severe AKI 
compared to patients with non-septic related AKI. The higher biomarker levels 
in patients with sepsis than non-sepsis might therefore partly be explained by this 
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difference. However, stratification into the different AKI stages showed a consistent 
difference in marker values between sepsis and non-sepsis, especially in patients with 
severe AKI (stage 3). 
Conclusion
The diagnostic accuracy of plasma NGAL for AKI is not affected by the presence of 
sepsis. Absolute biomarker values are increased in case of sepsis irrespective of AKI 
which, as a consequence, increases optimal cut-off values in these patients. Varying 
baseline SCr to define AKI does not impact on NGAL test accuracy.   
Future perspective
Our findings suggest that levels of plasma NGAL differ dependent upon the underlying 
etiology of AKI. This should be taken into account when NGAL is used into diagnostic 
models or in clinical decision making. 
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ESM-2: Patient cohort with baseline SCr 24 hrs prior to or at ICU admission 
114 Online data supplement
Electronic Supplementary Material (ESM)-3
E
S
M
-3
: 
Pa
ti
en
t 
ch
ar
ac
te
ri
st
ic
s,
 u
si
n
g
 b
as
el
in
e 
S
C
r 
2
4
 h
rs
 p
ri
or
 t
o 
or
 a
t 
IC
U
 a
d
m
is
si
on
 
N
on
-s
ep
si
s 
(N
=
58
3)
S
ep
si
s 
(N
=
80
)
N
o-
A
K
I
(N
=
50
2,
 8
6%
)
A
K
I
N
=
81
, 
14
%
)
P
N
o-
A
K
I
(N
=
41
, 
51
%
)
A
K
I
(N
=
39
, 
4
9
%
)
P
A
ge
, 
yr
5
8(
24
)
62
(2
4)
0.
02
56
(2
4)
62
(2
2
)
0
.1
3
M
al
e,
 n
(%
)
2
98
(5
9)
51
(6
3)
0.
54
20
(4
9)
18
(4
6
)
0
.8
1
A
PA
C
H
E 
II
 s
co
re
1
6(
10
)
24
(1
0)
<
0.
00
1
21
(9
)
25
(1
0
)
0
.0
1
N
on
-r
en
al
 S
O
FA
 s
co
re
4
(4
)
8(
6)
<
0.
00
1
6.
5(
4)
8.
5(
6
)
0
.0
3
D
ia
gn
os
ti
c 
gr
ou
p,
 n
(%
)
M
ed
ic
al
S
ur
gi
ca
l
N
eu
ro
lo
gi
ca
l
1
42
(2
8)
45
(5
6)
<
0.
00
1
32
(7
8)
37
(9
5
)
0
.0
8
2
36
(4
7)
24
(3
0)
7(
17
)
2(
5
)
1
22
(2
4)
12
(1
5)
2(
5)
0
R
en
al
 c
ha
ra
ct
er
is
ti
cs
B
as
el
in
e 
S
C
r,
 µ
m
ol
/l
6
8(
28
)
92
(6
5)
<
0.
00
1
90
(9
2)
11
6(
1
3
0
)
0
.1
0
U
P,
 m
l/
kg
/h
1
.1
(1
)
0.
8(
1)
<
0.
00
1
1.
1(
1)
0.
6(
1
)
<
0
.0
0
1
FB
, 
l/
da
y 
1
.9
(3
)
3.
6(
4)
<
0.
00
1
2.
8(
4)
3.
7(
5
)
0
.3
6
A
K
I 
st
ag
e 
1
-
38
(8
)
-
-
11
(1
4
)
-
A
K
I 
st
ag
e 
2
-
16
(3
)
-
-
7(
9
)
-
A
K
I 
st
ag
e 
3
-
17
(3
)
-
-
21
(2
6
)
-
In
fla
m
m
at
io
n 
pa
ra
m
et
er
s
W
B
C
, 
10
9 /
l
1
1.
1(
6)
11
.1
(7
)
0.
52
11
.5
(1
1)
15
.3
(1
1
)
0
.5
3
C
R
P,
 m
g/
l
7
9(
10
8)
10
1(
17
1)
0.
03
22
5(
12
8)
22
3(
1
3
2
)
0
.8
9
O
ut
co
m
e
C
V
V
H
, 
n 
(%
)
0
14
(1
7)
-
0
15
(3
9
)
-
M
or
ta
lit
y,
 n
 (
%
)
7
5(
15
)
34
(4
2)
<
0.
00
1
12
(2
9)
24
(6
2
)
0
.0
0
4
S
C
r:
 s
er
u
m
 c
re
at
in
e,
 S
O
FA
-2
4
: 
se
q
u
en
ti
al
 o
rg
an
 f
ai
lu
re
 a
ss
es
sm
en
t 
sc
or
e 
ov
er
 fi
rs
t 
2
4
 h
ou
rs
; 
A
PA
C
H
E
 I
I-
2
4
: 
A
cu
te
 P
h
ys
io
lo
g
y 
an
d
 C
h
ro
n
ic
 
H
ea
lt
h
 E
va
lu
at
io
n
 s
co
re
 o
ve
r 
fi
rs
t 
2
4
 h
ou
rs
; 
S
C
r:
 s
er
u
m
 c
re
at
in
in
e;
 U
P:
 u
ri
n
e 
p
ro
d
u
ct
io
n
 o
ve
r 
fi
rs
t 
2
4
 h
ou
rs
 p
er
 k
g
 id
ea
l 
b
od
yw
ei
g
h
t;
 F
B
: 
cu
m
u
-
la
ti
ve
 fl
u
id
 b
al
an
ce
 i
n
 fi
rs
t 
2
4
 h
ou
rs
; 
A
K
I:
 a
cu
te
 k
id
n
ey
 i
n
ju
ry
 n
et
w
or
k 
cr
it
er
ia
; 
W
B
C
: 
w
h
it
e 
b
lo
od
 c
el
l 
co
u
n
t;
 C
R
P:
 C
-r
ea
ct
iv
e 
p
ro
te
in
 a
n
d
 C
V
V
H
: 
co
n
ti
n
u
ou
s 
ve
n
o 
ve
n
ou
s 
h
em
ofi
lt
ra
ti
on
. 
V
al
u
es
 a
re
 p
re
se
n
te
d
 a
s 
m
ed
ia
n
 w
it
h
 i
n
te
rq
u
ar
ti
le
 r
an
g
e 
or
 a
b
so
lu
te
 n
u
m
b
er
s 
an
d
 p
er
ce
n
ta
g
es
, 
w
h
er
e 
ap
p
ro
p
ri
at
e.
115
Electronic Supplementary Material (ESM)-4 
Median (IQR) plasma NGAL values in patients with and without AKI stratified by sepsis, 
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ESM-5: Receiver operating characteristics curve analysis for the diagnosis of AKI 
stratified by sepsis using admission (A) and peak (B) plasma NGAL values
E
S
M
-5
: 
R
ec
ei
ve
r 
op
er
at
in
g
 c
h
ar
ac
te
ri
st
ic
s 
cu
rv
e 
an
al
ys
is
 f
or
 t
h
e 
d
ia
g
n
os
is
 o
f 
A
K
I 
st
ra
ti
fi
ed
 b
y 
se
p
si
s 
u
si
n
g
 a
d
m
is
si
on
 (
A
) 
an
d
 p
ea
k 
(B
) 
p
la
sm
a 
N
G
A
L 
va
lu
es
Pl
as
m
a 
N
G
A
L 
(n
g/
m
l)
A
U
C
 (
95
%
 C
I)
P
C
ut
-o
ff
S
en
s
sp
ec
N
on
-s
ep
si
s 
(N
=
54
2,
 N
=
73
 A
K
I)
0.
73
(0
.7
0-
0.
77
)
<
0.
00
01
26
6
6
3
8
0
S
ep
si
s 
(N
=
80
, 
N
=
39
 A
K
I)
0.
67
(0
.5
5-
0.
78
)
0.
00
73
30
4
7
7
5
5
Pl
as
m
a 
N
G
A
L 
(n
g/
m
l)
A
U
C
 (
95
%
 C
I)
P
C
ut
-o
ff
S
en
s
sp
ec
N
on
-s
ep
si
s 
(N
=
58
2,
 N
=
80
 A
K
I)
0.
76
(0
.7
3-
0.
80
)
<
0.
00
01
32
4
6
8
8
0
S
ep
si
s 
(N
=
80
, 
N
=
39
 A
K
I)
0.
73
 (
0.
62
-0
.8
2)
0.
00
01
97
9
5
6
8
8
A
K
I 
is
 c
la
ss
ifi
ed
 a
p
p
ly
in
g
 a
 b
as
el
in
e 
se
ru
m
 c
re
at
in
in
e 
va
lu
e 
S
C
r 
2
4
 h
rs
 p
ri
or
 t
o 
or
 a
t 
IC
U
 a
d
m
is
si
on
S
C
r:
 s
er
u
m
 c
re
at
in
e,
 N
G
A
L:
 p
la
sm
a 
N
eu
tr
op
h
il 
G
el
at
in
as
e-
as
so
ci
at
ed
 L
ip
oc
al
in
 A
U
C
: 
ar
ea
 u
n
d
er
 r
ec
ei
ve
r 
op
er
at
in
g
 c
u
rv
e;
 C
I:
 c
on
fi
d
en
ce
 
in
te
rv
al
 s
en
s:
 s
en
si
ti
vi
ty
 a
n
d
 s
p
ec
: 
sp
ec
ifi
ci
ty
. 
P=
0
.6
3
 f
or
 d
if
fe
re
n
ce
 i
n
 A
U
C
 b
et
w
ee
n
 n
on
-s
ep
si
s 
an
d
 s
ep
si
s 
p
at
ie
n
ts
.
117
Electronic Supplementary Material (ESM)-6
ESM-6: Plasma NGAL concentrations in patients stratified for sepsis and (severity of) AKI
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SCr baseline definitions
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Chapter 5
Time and site of injury affect the predictive 
value of urinary biomarkers for acute kidney 
injury in non-septic, critically ill patients
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Abstract
Background: The predictive value of urinary biomarkers for acute kidney injury (AKI) 
may depend on the time interval after tubular injury and its predominant site, thereby 
explaining in part their heterogeneous performance reported in the literature. We studied 
the influence of these factors on the predictive values of tubular proteins, measured 
before the rise of serum creatinine (SCr) in critically ill, non-septic patients. 
Methods: Seven hundred adult critically ill patients were prospectively included for 
urine measurements at four time-points prior to rise in serum creatinine (T=0, -16, -20 
and -24 h). Patients with sepsis and or AKI at ICU entry were excluded. The urinary 
excretion of the proteins neutrophil gelatinase-associated lipocalin (NGAL) and kidney 
injury molecule-1 (KIM-1) up-regulated in distal and proximal tubules, respectively, 
were measured as well as the constitutive cytoplasmatic enzymes π- and α-glutathione-
S-transferase (GST), released by distal and proximal tubules, respectively. 
Results: 543 subjects were eligible for further analysis; 49 developed AKI in de first 48 
h. Both NGAL (P=0.001 at T=-24 vs no-AKI) and KIM-1 (P<0.0001 at T=0 vs. no-AKI) 
concentrations gradually increased until AKI diagnosis, whereas π- and α-GST peaked 
at T=-24 before AKI (P=0.006 and P=0.002 respectively vs no-AKI) and showed a rapid 
decline afterwards. The predictive values at T=-24 prior to AKI were modest for π- and 
α-GST, whereas NGAL predicted AKI already at T=-24 and even better when the time 
interval to AKI decreased (area under the receiver operating characteristic curve AUC 
0.79, P<0.0001). KIM-1 was a good discriminator at T=0 only (AUC=0.73, P<0.0001). 
Conclusions: Our data suggest that the predictive value for developing AKI depends 
upon time and predominant site of tubular injury, with decreasing predictive values in 
time of constitutive enzymes and increasing values for upregulated proteins, and higher 
predictive values of markers of distal than of proximal injury.
Key words:  urinary biomarkers, AKI, injury site, NGAL, KIM-1, Pi-GST and alpha GST.
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Background
There is ongoing search for biomarkers for AKI prediction, which may help, in the 
future, to guide preventive and therapeutic measures to benefit patients [1-13]. 
The AKI-induced up regulation of low molecular weight proteins, such as neutrophil 
gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1), and their 
subsequent release and excretion into urine have been studied in patients with or at 
risk for AKI [6-9, 11, 13-18]. Currently, NGAL, presumably from distal tubular origin 
at least in experimental AKI [19], is the most frequently described, albeit imperfect, 
biomarker of human AKI and is considered as a reference standard [3, 5, 6, 8-13, 20, 
21]. Still, there is a markedly heterogeneity of its reported predictive power for AKI. 
The clinical value of KIM-1, a predominantly ischemic proximal tubular injury marker 
[1, 4, 5], remains uncertain, with reports suggesting superiority [1, 4] or inferiority 
[3, 5, 13] compared to other markers. The constitutive cytoplasmatic enzymes π- and 
α-glutathione-S-transferase (GST) are detectable in urine when the integrity of the cell 
wall of distal and proximal tubules is damaged, respectively. Therefore, urinary release 
of GSTs reflects the site of tubular injury [22]. The few clinical studies on the predictive 
value of these enzymatic markers for AKI are conflicting [2, 3, 9, 23] and a comparison 
with urinary NGAL is limited to post cardiac surgery only [9]. The available literature 
thus reports heterogeneous predictive performance of biomarkers for AKI in different 
patient populations and conditions, such as adult vs pediatric patients, sepsis vs non-
sepsis states, surgical vs non-surgical conditions, developing vs established AKI, fixed 
vs non-fixed intervals between injury and sampling.   
In this study we wished to evaluate predictive performance of AKI biomarkers as a 
function of time (to sampling) and site of tubular injury in non-septic patients, since 
predictive values and optimal cutoff levels of AKI markers may differ between septic and 
non-septic AKI [24] . In contrast to our previous study including AKI at entry [11], the 
primary endpoint for the current study was the development of AKI within 48 h after ICU 
admission. Indeed, predicting is more useful than confirming established AKI and many 
studies lumped developing and established AKI together, thereby potentially leading to 
overestimation of predictive values [1-6, 8-10, 12, 13, 21]. 
Methods
Setting
This is a prospective single center cohort study in a 30-bed closed format university 
hospital intensive care unit (ICU) on which general surgical, trauma, medical, neurological 
and neurosurgical, but not cardiac surgery, patients are treated. All consecutively 
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admitted adult critically ill patients, between September 1, 2007, and April 1, 2008, 
were considered eligible. Exclusion criteria were age under 18 years, refusal of informed 
consent, a history of nephrectomy, documented chronic kidney disease (CKD) (>stage 
3) or kidney transplantation and a diagnosis of sepsis at the time of ICU entry. The study 
was approved by the institutional review board of the Erasmus MC University Medical 
Center in Rotterdam, the Netherlands. Deferred consent was used with written informed 
consent obtained from the participants or their health care proxy within 48 h after ICU 
admission. In the case of consent refusal (n=6, 0.9%) the collected urine specimens 
were appropriately destroyed. This study is a sub-study of one previously reported [11], 
with other biomarkers and focusing on developing AKI. 
Protocol, sample collection and processing. Demographic data were recorded, including 
severity of illness scores, several renal and outcome parameters such as the serum 
creatinine at hospital discharge, the duration of stay on the ICU in days, the mortality 
rate at 28 days after ICU admission and in the hospital. Serum creatinine values were 
available at the time of admission and daily thereafter at 6:00 am until 72 h after entry. 
The serum creatinine was measured in the hospital’s clinical chemical laboratory with 
the Roche enzymatic kit which is traceable to a reference method based on isotope 
dilution mass spectrometry. Urinary output and fluid balances were recorded. At ICU 
admission (T=0) and at T=4, 8, 24 hrs thereafter urine samples were collected using 
an urine catheter. The samples were processed in the hospital’s laboratory and the 
supernatants stored at -80 °C.  NGAL (Biosite Inc Alere, San Diego, Clf, USA, using the 
Triage® immunoassay), KIM-1, π- GST, and α-GST (Argutus Medical, Dublin, Ireland) 
concentrations were measured using research-based immunoassays. The detection limits 
for the urine NGAL assays was 2.6 - 4100 ng/ml, respectively. The assays’ coefficient of 
variation was 13.9%. The π- GST assay detection limits are 3.12-100 ng/ml, for α-GST 
6.25-200 ng/ml and for KIM-1 0-10 ng/ml. The average assays’ coefficient of variation 
in this study were 4%, 3% and 1%, respectively. 
Definitions
Baseline serum creatinine was defined as the steady state level four weeks to six months 
prior to ICU admission. If not available, the admission value was applied as baseline. Criteria 
for sepsis were clinically suspected or confirmed infection, a temperature above 38.5  C̊ 
or below 36.0  C̊, tachycardia (>90 beats/min) and tachypnea (>20/min) or necessity for 
mechanical ventilation, and leukocytosis >12 x109/L or >10% bands, or leucopenia <4 x109/L. 
AKI was defined using the acute kidney injury network (AKIN) classification for changes in 
serum creatinine relative to a steady state baseline value (AKIN 0= no-AKI, AKIN 1= serum 
creatinine increase >50% or an absolute serum creatinine rise of 0.3 mg/dL (=26.5 µmol/L) 
compared to baseline, AKIN 2= serum creatinine increase >100% and AKIN 3= serum 
creatinine increase >200%) without using the urine output (UP) criteria. In order to plot the 
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expression of biomarkers preceding AKI, the time-points after ICU admission were recoded 
into time-points preceding AKI. AKI occurred either at T=24 or T=48 after ICU admission. 
The time-point of AKI was recoded to T=0 and the available measurements recoded relative 
to T=0 (T= -48, T= -44, T= -40, T= -24, T= -20 and T= -16 hrs). Fifty-six patients had more 
than one ICU admission and only the data of the first admission were used.
Statistical analysis
Patients were grouped according to no-AKI or developing AKI within the first 48 h of 
admission. Most continuous data were distributed non-normally (Kolmogorov-Smirnov 
test P<0.05). We compared developing AKI with no-AKI and univariate analysis for 
continuous variables was with help of the Mann-Whitney U test and for categorical 
variables using the χ2 or Fisher exact test. Tests were two-tailed throughout. Receiver 
operating characteristics curve (ROC) analysis was used in patients with developing 
AKI to assess the predictive value of the biomarkers. The area under de curve (AUC) 
with 95% confidence intervals [95% CI] was calculated and compared. The optimal cut 
off level (Youden index) was calculated with the corresponding sensitivity, specificity, 
positive and negative likelihood ratios. Statistical analyses were performed with the 
statistical software package SPSS, version 16.0 (SPSS, Chicago, IL, USA) for windows 
and MedCalc for Windows, version 9.5.0.0 (MedCalc Software, Mariakerke, Belgium). 
Data are reported as number (percentage) or median (interquartile range), where 
appropriate. However, means and standard errors of the mean (SEM) were used in 
the time course graphs for the sake of clarity. A P≤0.05 was considered statistically 
significant and exact values are given.
Results
Patients’ characteristics 
Seven hundred consecutive ICU admissions were included. Six patients refused consent 
(0.9%), 6 patients had undergone a nephrectomy (0.9%) and 25 patients had chronic 
kidney disease (CKD) stage 3 or kidney transplant (4%). Of the remaining 607 patients, 
156 subjects had AKI within the first 48 h of admission (25%). Of those, 99 cases had AKI 
at entry (established AKI=63.5%) and 57 developed AKI (developing AKI=36.5%) within 
48 h. Eight patients with developing AKI were diagnosed with sepsis at ICU admission 
(Figure 1). Patients with developing AKI were older, more severely ill and more often male 
(Table 1). Furthermore, developing AKI patients had a higher pre-admission baseline serum 
creatinine and a higher cumulative fluid balance within the first 24 h of ICU admission. At 
hospital discharge SCr values were higher in patients who had an episode of AKI compared 
to patients without, 28-day and hospital mortality rates were higher as well.
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Biomarker patterns following ICU admission 
The biomarker levels following ICU admission for patients with developing AKI and 
those without AKI are shown in Figure 2A. This panel represents the not-recoded data. 
The concentrations of the upregulated proteins NGAL and KIM-1 increase over time 
following ICU admission, with NGAL showing an increasing pattern right from the time 
of admission (P<0.0001) and KIM-1 differentiating between no-AKI and AKI T=24 
hours for the first time (P=0.008). The concentrations of KIM-1 in patients without AKI 
increased over time after ICU admission. The constitutive enzymes π- and α-GST both 
display decreasing concentrations and remain higher up until 8 hours after admission 
compared to no-AKI (P≤0.048 and P≤0.017 respectively).
Biomarker patterns preceding AKI
Figure 2B shows the biomarker patterns before the time of AKI. All available no-AKI 
biomarker values were pooled to represent the no-AKI concentration in the graph 
represented at T=-72. The upregulated proteins KIM-1 and NGAL displayed a gradual 
increase in concentrations prior to SCr increase. KIM-1 being different compared to 
patients without AKI right at the time of AKI (T=0, P<0.0001) in contrast to NGAL 
showing a quicker response with different concentrations compared to no-AKI starting 
at 24 hours prior to the time of AKI (P=0.0005). The constitutive enzymes, π- and 
Figure 1: Study cohort flow chart. N: number; AKI: acute kidney injury; established AKI: AKI at the time of 
ICU admission and developing AKI: AKI developing at or after 24 hours of admission. 
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Figure 2: Biomarker patterns after ICU admission (A) and preceding AKI (B). Biomarker concentrations are ex-
pressed in ng/ml and data represent mean (standard error of the mean; SEM). NGAL: Neutrophil gelatinase-as-
sociated lipocalin; KIM-1: Kidney injury molecule-1; GST: glutathione-S-transferase; AKI: acute kidney injury. 
Mean biomarker concentrations in patients with AKI vs patients without AKI at each time-point were compared 
using Mann-Whitney U test (A) and mean biomarker concentrations in patients with AKI were compared to the 
pooled mean value of all available no-AKI measurements using Mann-Whitney U test (B). Panel A represents 
the un-recoded data plotted against time after ICU admission, Panel B represents the recoded data prior to rise 
in SCr.
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α-GST, had their peak concentrations 24 and 20 hours prior to the time of rise in SCr 
(T=0), respectively, as compared to patients without AKI (P=0.006 and P=0.0018). 
After a sudden peak, biomarker concentrations declined quickly prior to the time of AKI.
Prediction of AKI
Table 2 shows the area under de curves (AUC’s) for the prediction of developing 
AKI for each individual biomarker at different time points. NGAL displays the most 
consistent predictive performance starting 24 hours before AKI (AUC=0.66, P=0.0005) 
and increases closer to the endpoint of AKI (AUC=0.79, P<0.0001). In contrast, KIM-1 
“predicts” AKI only at the moment of rise in SCr for the first time (AUC=0.73 P<0.0001). 
For both π- and α-GST the predictive power is modest (AUC=0.65 for both) even at peak 
marker concentrations 24 and 20 hours prior to AKI.
Discussion
The present study suggests that the predictive performance of biomarkers for 
developing non-septic AKI depends on the time of sampling relative to the time of AKI 
and therefore on the, otherwise unknown, time interval between sampling after tubular 
injury. Furthermore, it suggests that the upregulated proteins show a consistent and 
gradually increasing signal over time whereas the constitutive enzymes display a narrow 
time window of expression. NGAL outperforms KIM-1 in early expression prior to AKI, 
suggesting greater distal than proximal injury.
The predictive value of NGAL for (non-septic) AKI in this study is in accordance with 
other work [3, 5, 6, 8-13, 20, 21, 25]. The expression pattern of NGAL prior to rise 
in SCr is early and consistent with the predictive power increasing closer to the time 
of AKI. This latter observation endorses the idea that the time-to-injury relationship 
matters and should be known for a correct interpretation of its predictive value for AKI. 
KIM-1’s expression was less accurate and late (at the time of SCr increase) compared to 
NGAL in the current study and this confirms work by others in adult critically ill patients 
[1, 3, 4, 7, 9]. Moreover, the predictive value of KIM-1, only slowly increasing in time 
after renal injury, as our data suggest, is higher if AKI has already developed, as in 
cardiac surgery,  rather than if AKI develops in the course of time, as in our study [1, 
4, 5, 9]. The rise in KIM-1 over time even when AKI does not develop can perhaps be 
explained by subclinical injury, since KIM-1 is a transmembrane glycoprotein exclusively 
present in epithelial cells surviving after injury and facilitating phagocytosis of necrotic 
cell debris [1, 9]. 
π- and α-GST were only modest predictors for AKI in this population with slightly 
better or similar results compared to those reported in adult cardiac surgery patients 
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(AUC=0.54 [95% CI 0.42-0.66] [9, 26] but similar in another cohort of general critically 
ill patients [25]. In an older study, the markers were suggested to be superior to other 
enzymes AUC=0.93 [0.74-0.99] and 0.89 [0.69-0.98] respectively [23], these results 
were not reproduced in following studies. Several other studies described the diagnostic 
performances in established AKI, which results are incomparable to the present data 
[2, 26, 27]. Especially for these enzymatic markers, the time of sampling in relation 
to the injurious hit seems to be critical for their ability to predict a rise in SCr later on. 
This might make this category of biomarkers less well applicable in patients without 
a circumscribed time point of renal injury such as is the case in general ICU patients. 
However, due to the sudden changes in concentrations in urine their applicability might 
be more appropriate in a setting of monitoring renal toxic effects of drugs and contrast 
agents.
There are several limitations to the current results. Despite the large initial number of 
included patients the subset of patients with developing AKI was relatively small, since 
64% of the AKI patients had AKI at ICU entry and they were excluded for the current 
analysis. The subset of patients with developing septic AKI was even smaller and did 
not allow sufficient data analysis, although it would have been interesting to study the 
possible differences in biomarker expression between both septic related and non-septic 
related AKI. In spite of the recognition of serum creatinine as a poor indicator of renal 
injury, confounded, among others by varying tubular secretion, it is still used in many 
studies [3, 12, 28]. Therefore, the usefulness of potentially sensitive markers might be 
underestimated. We believe this phenomenon is reflected by our data, which indicate 
the presence of subclinical tubular injury in no-AKI patients (increase in KIM-1 levels in 
patients without AKI according to AKIN classification). Urinary biomarkers can be used in 
non-anuric AKI only, narrowing their clinical applicability. Controversy exists on whether 
correction for urinary creatinine concentrations is necessary for the interpretation of 
the results. We believe that normalization to urine creatinine concentration poses a 
limitation by itself since patients with AKI are not in a steady state creatinine turnover. 
Furthermore, several authors have shown that this effort does not contribute much [1, 
2, 5, 6, 9, 13, 23]. 
Conclusions
Our current data suggest that the expression pattern of different biomarkers such as 
upregulated proteins and constitutive enzymes and the time of sampling in respect 
to the time of actual cellular injury may partly explain the heterogeneity of predictive 
values. Furthermore, predictive values depend on the predominant site of injury. These 
factors should be taken into account in future studies.
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Abstract
The early detection and diagnosis of acute kidney injury (AKI) with the standardization 
of novel kidney-injury specific biomarkers is one of the highest research priorities in 
nephrology.  Accordingly, the majority of studies of novel AKI biomarkers have focused 
on the early diagnosis of AKI using serum creatinine-based definitions as the gold 
standard.  However, another potential application of kidney-injury specific biomarkers is 
for guiding decisions on when to initiate renal replacement therapy (RRT). The purpose 
of this review is to summarize recent findings concerning some of the more promising 
AKI biomarkers on their capacity, either alone or integrated with traditional surrogate 
measures of kidney injury, for early prediction of whether patients will develop severe 
AKI requiring RRT. 
Some studies which have examined NGAL, cystatin-C, NAG, KIM-1, and α1-microglobulin, 
among others, have suggested these novel biomarkers have the potential to distinguish 
patients in whom RRT will be needed. This would imply that these biomarkers may 
be integrated into clinical decision algorithms, and could synergistically improve our 
current ability to predict worsening AKI and need for RRT.  However, published studies 
have many recognized limitations , which preclude our ability to adopt their findings 
into clinical practice today.  While currently available data are not sufficient to conclude 
that biomarkers should be used routinely for clinical decision making for RRT initiation, 
additional data may in the future significantly modify the clinical variability for initiation 
of RRT, and potentially translate into improved outcomes and cost-effectiveness.  Finally, 
we propose a potential approach to future biomarker strategies for RRT initiation, 
integrating these biomarkers with “traditional” clinical factors.
Key words:  acute renal failure, acute kidney injury, α1-microglobulin, biomarkers, 
cystatin C, dialysis, Kidney Injury Molecule-1, N-acetyl-β-D-glucosaminidase, Neutrophil 
Gelatinase Associated Lipocalin (NGAL), renal replacement therapy
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Introduction
It is well known that serum creatinine (sCr) is an unreliable indicator during acute 
changes in kidney function.  Its value can vary widely with age, sex, muscle mass, 
medications and hydration status. Furthermore, its concentration may not change until 
a significant amount of kidney function is lost, therefore it carries the risk of missed 
therapeutic opportunity because of the time lag between the inciting insult and the 
diagnostic elevation. These limitations are felt to contribute to the still dismal clinical 
outcomes associated with acute kidney injury (AKI).
As a consequence, the American Society of Nephrology has assigned the highest 
research priority to the standardization and/or discovery of new biomarkers of AKI. 
In response there has been great scientific enthusiasm and abundant publications 
on these biomarkers.  Most of the investigations have focused on the ability of these 
biomarkers to detect established AKI or the early diagnosis of AKI (almost universally 
defined as defined by sCr-based definitions). Several promising candidates have 
emerged, demonstrating reasonable diagnostic performance for AKI up to 48 hours 
prior to a significant change in sCr [2, 3].  With the advent of commercially available and 
standardized platforms for either point-of-care or rapid centralized central laboratory 
measurements for some of these, the medical community has shown great interest in 
incorporating such measurements into clinical practice.
At present, the actual clinical utility of these early biomarkers remains largely untested 
with a key question being whether they would add anything to management beyond the 
information provided by using a conventional, sCr-based diagnosis.  Although a case 
could be made that early AKI detection could encourage “avoidance of harm”, such as 
nephrotoxic medications or premature stepdown from the intensive care unit (ICU), 
the reality in 2010 is that we do not yet have much to offer in terms of therapeutics. 
One area of potential clinical use is that of guidance in the decision to initiate renal 
replacement therapy (RRT) in patients with AKI.  Aside from predicting AKI, several 
biomarker studies have also examined prediction for “hard” outcomes such as need for 
RRT or death.  In this next section we will briefly review selected studies which have 
looked at the use of novel biomarkers for the prediction of subsequent need for RRT.  
Biomarker studies and need for RRT
Neutrophil gelatinase-associated lipocalin (NGAL)
High throughput functional genomic studies have identified NGAL as one of the most 
upregulated transcripts in the kidney very early after acute injury. Downstream proteomic 
studies have also revealed the 25 kD NGAL protein to be one of the earliest and most 
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robustly produced proteins in the kidney after ischemic or nephrotoxic AKI in animal 
models [4].  It can be measured in the blood and the urine.  Both have been shown to 
be an early predictor of AKI in several clinical settings, including cardiac surgery [5], 
radio contrast exposure [6], trauma [7] and in critical illness [8].
Several studies have examined the clinical endpoint of RRT initiation using NGAL, of 
which nine have been summarized in a recent meta-analysis [9].  Included studies for 
this endpoint represented a variety of clinical settings, including both children and adults 
(Table 1). Either urine or plasma/serum NGAL were measured. The overall incidence of 
RRT in the included studies was 4.3%, which was slightly higher in the ICU population, 
ranging from 5-15% [8, 10, 11].  The pooled analysis yielded an area under the Receiver 
Operator Characteristic curve (AUC) 0f 0.782 (95% CI, 0.648-0.917) for discriminating 
patients who would receive RRT associated with AKI. For a cut-off NGAL value of 278 ng/
mL, the sensitivity was 76% and specificity was 80%; however, it is difficult to translate 
this to the patient’s bedside because of the diverse patient populations, specimens 
and assays used in obtaining this estimate.  However, this remains the largest pool 
of patients studied so far on NGAL, with 1948 patients from 9 studies included in this 
analysis for prediction of need to initiate RRT.
In a subsequent study, the median enrollment urine NGAL levels were also found to be 
significantly higher in the 17/490 (3.5%) patients who received acute RRT (548 ng/
mg Cr [IQR 156-466), versus the 473/490 (96.5%) who did not (61 ng/mg Cr [IQR 
17-232]) [12].  While no specific cut-off was evaluated, there was over a two-fold 
increase in the adjusted risk for RRT with increasing urine NGAL levels (adjusted Hazard 
Ratio [HR] for log-transformed urine NGAL (2.6 [95% CI, 1.6-4.4]). While these data 
require further confirmation given the relatively low event rate for patients initiated on 
RRT, these observations imply NGAL may have important interaction with conventional 
criteria to aid in the clinical decision to initiate RRT.
Cystatin C
Cystatin C is a 13 kDa nonglycosylated cysteine protease inhibitor produced by all 
nucleated cells in a constant rate unaffected by muscle mass. In healthy subjects, 
plasma CyC (pCyC) is excreted through glomerular filtration and metabolized completely 
by the proximal tubules. There is no evidence of tubular secretion and therefore it is 
normally not found in urine in significant amounts. Accordingly, urinary excretion of 
CyC (uCyC) reflects tubular damage [13].  Several studies and a subsequent meta-
analysis demonstrated the superiority of pCyC compared with sCr for detection of minor 
reductions and acute changes in glomerular filtration rate [14]. More recently, it has 
been shown that pCyC levels are influenced by abnormal thyroid function [15, 16], 
immunosuppressive therapy [17] and the presence of inflammation or malignancies 
[18, 19]. 
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In human studies, both pCyC and uCyC have been shown to predict AKI [20, 21], 
although its superiority over sCr has not been a universal finding [22].  In terms of RRT 
requirement, plasma and serum CyC (sCyC) have been studied in different settings 
(Table 2).  In a general ICU, sCyC was measured in 85 patients at high risk for AKI [20]. 
The capacity to predict need for RRT was tested at three time points: on Days -2, -1 and 
0 of reaching RIFLE-Risk.  The AUC for sCyC were 0.69, 0.75 and 0.76, respectively. 
Using a ≥50% increase in sCyC from Day-3 (considered as baseline), the sensitivity and 
specificity improved going from Day-2 to Day 0 (Table 2).   Another study measured 
plasma Cr (pCr) and pCyC in 444 adults on ICU admission [23], of whom 124 already 
had AKI on entry. In the entire cohort, pCyC was moderately predictive of death or 
RRT (AUC 0.61, 95% CI, 0.53-0.68) and performed similarly as pCr (AUC 0.60, 95% 
0.51-0.67).  In an analysis excluding patients with AKI on admission, pCyC performed 
slightly better (AUC 0.84, 95% CI, 0.69-0.99) than pCr (AUC 0.77, 95%CI, 0.59- 0.94) 
for RRT prediction.  
Serum CyC was measured in 200 AKI patients from the nephrology consult service 
(mean sCr 300 µmol/L at enrollment), of whom 83 died or underwent RRT [24]. 
Serum CyC had an AUC of 0.65 (95% CI, 0.58-0.73) for this composite endpoint.  This 
was inferior to a basic prediction model using APACHE II, liver disease, sepsis and 
mechanical ventilation (AUC 0.82). When sCyC was added to this basic model, there was 
no significant improvement in performance (AUC 0.83). Furthermore, the diagnostic 
accuracy was quite similar whether sCr, serum urea nitrogen or urine output were used 
instead of sCyC (AUCs 0.83-0.84). 
In cardiac surgery, two small studies demonstrate divergent results. Koyner et al 
included 72 adults following cardiac surgery; of these 34 developed AKI, of whom 7 
subsequently needed RRT [25]. The authors concluded that pCyC was not a useful 
predictor for AKI development (AUCs for various time points after cardiopulmonary 
bypass [CPB] 0.617-0.631), and not further analyzed for RRT prediction. In contrast, a 
similar study on 100 adult patients, of whom 5 reached a composite endpoint of RRT or 
death, found excellent performance for prediction of this endpoint for pCyC (AUC 0.99, 
95% CI, 0.98-0.99)[26]. In both studies, the absolute number of patients who reached 
the RRT or composite endpoint was quite small. The reason for discrepant results is 
not immediately clear. Unfortunately, the clinical utility of pCyC to predict RRT initiation 
from these data may be limited, due to many studies having relatively low event rates 
and using composite endpoints that may compete (i.e. death  or RRT) and that no clear 
superiority to serum creatinine was observed.
Urine cystatin C has also been studied (Table 2).  Several tubular proteins and enzymes 
were tested for their prognostic ability in 73 consecutive patients with established non-
oliguric AKI (median sCrs 159-194 µmol/L), of whom 26 required RRT a median of 4 
days after enrollment [27]. Good diagnostic performance was seen with uCyC (AUC 
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0.92, 95% CI, 0.86-0.96) and α1-microglobulin (AUC 0.86, 95% CI, 0.78-0.92). At 
a cut-off of 1g/mol Cr, uCyC appeared to be highly sensitive (92%) and reasonably 
specific (83%) for predicting RRT. No comparison was made with sCr. Results are, 
however, not consistent.  In another study (discussed below), uCyC was not predictive 
of RRT in 102 patients recruited from a nephrology consult service [21]. Unfortunately, 
this study did not report the sCr of the patients, precluding meaningful comparison 
with the previous study.  In one of the cardiac surgery studies mentioned above, uCyC 
performed better for AKI prediction than did pCyC [25]. At various timepoints after CPB, 
uCyC concentrations were highest in AKI with RRT, followed by AKI without RRT, then 
No AKI (p≤0.01 for 3-group comparison). While no specific analysis was performed on 
the operative characteristics of uCyC to predict RRT initiation, these observations are 
encouraging, yet also appear inconsistent. Additional confirmatory evidence is needed 
from studies enrolling a population of patients with AKI with higher risk features for RRT 
initiation. 
N-acetyl-β-D-glucosaminidase (NAG) 
NAG is a lysosomal enzyme (> 130 kDa) that is localized in several human cells including 
the renal tubules. Due to its large molecular weight it precludes glomerular filtration, 
implying that urinary elevations have a merely tubular origin. Increased activity 
suggests injury to its cells but also may reflect increased lysosomal activity without cell 
disruption. NAG catalyzes hydrolysis of terminal glucose residues in glycoproteins and is 
the most active glycosidase found in proximal tubular epithelial cell lysosomes. Urinary 
NAG activity remains elevated during different kinds of active renal disease [28].
The diagnostic and prognostic ability of 9 urinary biomarkers, including NAG, was 
evaluated in a cross sectional study with 102 patients with established AKI compared 
to 102 subjects without AKI [21]. The non-AKI subjects included healthy controls, ICU 
patients and subjects who underwent coronary angiography, while AKI patients were 
recruited at the time of nephrology consultation. In age-adjusted analysis using log-
transformed biomarker values, NAG was found to be a significant predictor for RRT, 
mortality and their composite endpoint among AKI patients (Table 3). The median 
normalized NAG level in AKI patients who underwent RRT was 0.06 U/mg Cr, versus 
0.02 U/mg Cr in those who did not. 
The same authors studied urine NAG and Kidney Injury Molecule-1 (KIM-1) in 201 
consecutive adult patients with AKI on the nephrology consult service [29]. The AUC for 
NAG for the composite outcome of RRT requirement or hospital death was 0.71 (95% 
CI, 0.63-0.78), better than that of sCr (0.60, 95% CI, 0.52-0.68) or urine output (0.65, 
95% CI, 0.57-0.73). There were significantly higher odds (Odds Ratio [OR] 9.1, 95% 
CI,3.7-22.7) for RRT or death in the NAG fourth quartile group compared to the first 
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quartile.  This persisted, though attenuated, after adjustment APACHE II scores, MOF 
scores, and other variables including oliguria and sepsis (OR 4.8, 95% CI, 1.7-13.1).
In the above-mentioned study by Herget-Rosenthal et al, the urinary excretion of 
NAG was significantly higher in patients requiring RRT [27]. On ROC curve analysis, 
the AUC for NAG was 0.81 (95% CI,0.73-0.88), slightly inferior to that of uCyC and 
α1-microglobulin. At a cut-off of 4.5 U/mmol Cr, NAG was a sensitive (85%) but non-
specific (62%) predictor for RRT.  The authors concluded that tubular proteinuria was 
superior to tubular enzymuria in differentiating the need for RRT in AKI patients.  A 
possible explanation might be that the early peak of the enzymuria was missed in 
these patients who already had established AKI at enrollment.  In a study of 635 
unselected patients presenting to the emergency room, urine NAG was not predictive 
of a composite outcome of nephrology consultation, ICU admission, RRT initiation and 
mortality on multivariable analysis which included sCr and blood urea nitrogen (BUN) 
[30] (Table 3). Urine NAG also appears to hold promise as added clinical information to 
aid in early decision-making for RRT initiation; however, similar to prior studies, further 
confirmatory data would be needed that focuses specifically on the additive/synergistic 
value of urine NAG for predicting RRT alone rather than as part of a composite outcome.
Kidney Injury Molecule-1 (KIM-1)
KIM-1 is a type I transmembrane glycoprotein with a cleavable ectodomain which is 
localized in the apical membrane of dilated tubules in acute and chronic injury [31]. 
There are two homologues forms of KIM-1 with differences in their C terminal portion; 
one is expressed in the liver, the other in the kidney. Further expression of those 
homologous forms is reported in the cochlea, in clear cell-type renal carcinoma which is 
associated with proximal tubular cell dedifferentiation and by subpopulations of T-cells 
(TIM-1) [32]. KIM-1 and its soluble ectodomain in urine (90 kDa) are believed to play a 
role in the regeneration processes after epithelial injury.
In the study by Liangos et al, the AUC for prediction of RRT or death for KIM-1 was 0.61 
(95% CI, 0.53-0.61), comparable to that of sCr and urine output [29]. On adjusted 
analysis, patients in the highest KIM-1 quartile had a 3.2 fold higher odds (95% CI, 
1.4-7.4) for the composite outcome compared to patients with the lowest quartile. On 
multivariate analysis, this was no longer significant.  In another study by the same 
authors, KIM-1 was not a significant predictor for RRT, but was a significant predictor 
for mortality [21] (Table 3).
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Creating biomarker strategies for RRT init iation
Although results are encouraging for some biomarkers, there remains important 
challenges to creating and testing biomarker-based strategies for RRT initiation.  First, 
while a “hard” outcome such as RRT may be perceived as relatively uniform across 
various studies, this still has the limitations of a surrogate outcome.  Due to the wide 
practice variation in timing of initiation of RRT and the lack of broad consensus, the 
initiation of RRT remains somewhat subjective as a hard endpoint.  The decision to 
start RRT is strongly influenced not only by individual physician practice, but also by 
sCr and urine output, the very same conventional markers whose shortcomings we 
lament. Furthermore, such a decision may also be affected by factors unrelated to 
either patient or physician, such as organizational or logistical issues [33].  Second, a 
limitation of these studies is the variable timing of specimen collection. These include 
at ICU admission and at the time of nephrology consultation, the timing of which can 
vary from institution to institution. Third, most analyses have been based on a single 
specimen.  Because different biomarkers may have varying kinetics following AKI, 
timing of specimen collection with respect to the relevant kidney insult may significantly 
affect their predictive values.  Fourth, in many of these studies the number of days from 
biomarker measurement to RRT initiation was not stated. Therefore we cannot comment 
as to whether it could help the clinician make an “early” decision to initiation RRT. Fifth, 
some studies have a conceptual approach to the analysis for prediction of RRT. While 
analysis by quartiles [29] or by “per 1-SD increase”[24] can potentially confirm that a 
higher biomarker level is predictive of RRT, it does not provide clinically meaningful cut-
off values which can be used at the bedside.  Lastly, only two of these studies adjusted 
the analysis for “traditional” measures used to decide when to initiate RRT, such as sCr, 
BUN [30] or oliguria [29].
Timing of RRT initiation has been the focus of many scientific publications. In general, 
the currently available data, many from observational studies,  suggest a trend towards 
reduced mortality and better renal recovery with earlier initiation of RRT [34-36]. 
However, no sufficiently powered RCT to date has shown a survival or kidney recovery 
benefit to earlier RRT initiation compared with standard of care or for more conventional 
indications. Currently, there exists no broad consensus to guide clinicians on this 
important issue.  Accordingly, we have recently proposed an opinion-based clinical 
algorithm to aid in the decision on when to consider initiation of RRT in critically ill 
adults, giving a more quantitative characterization of “timing” using RIFLE/ AKIN, as 
well as incorporating several patient-specific factors [33]. One interesting question to 
ponder is whether biomarkers would be useful to better inform this decision.
Studies have demonstrated better outcome in patients who were started on RRT while 
they were still in RIFLE-Risk or Injury, as compared to those who started RRT when 
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Box 1:
Optimize resuscitation: 
Intravascular volume
Cardiac output
Mean arterial pressure 
Intra‐abdominal pressure 
Re‐assess the patient :
AKI severity & trend
Illness severity & trajectory 
Initial response to initial resuscitation therapy 
Box 2:
Are certain aggravating circumstances present? 
Rapidly worsening AKI
Rapidly worsening  illness severity
Hypercatabolic state
Refractory fluid overload and/or accumulation
Severe sepsis
Permissive hypercapnea 
Reduced renal reserve
Low probability for rapid renal recovery
Dialyzable toxins 
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Figure 1: Proposed approach to future biomarker strategies for RRT. AKI – acute kidney injury; BM – biomark-
er; ICU – intensive care unit; RIFLE – Risk Injury Failure Loss Endstage renal disease; RRT – renal re lace-
ment therapy. Box 1: Optimize resuscitation: intravascular volume, cardiac output, mean arterial pressure, 
intra abdominal pressure. Re-assess patient: AKI severity and trend, illness severity and trajectory amd initial 
response to resuscitation therapy. Box 2: Are mitigating circumstances present?: Rapidly worsening AKI, or 
illness severity, hypercatabolic state, refractory fluid overload, severe sepsis, permissive hypercapnea, reduced 
renal reserve, low probablityt for rapid renal recovery and dialyzable toxins. 
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they were in RIFLE-Failure, although interpretation of these studies is confounded by 
the failure to include patients who recover renal function or die without ever receiving 
RRT [37, 38].  But clearly we cannot provide renal support for all critically ill patients 
with  Risk/ Stage 1 or Injury/ Stage 2.  A considerable proportion of these patients are 
likely to spontaneously recover renal function before developing significant sequelae 
such as fluid overload or uremia, and therefore the potential benefits of RRT may not 
exceed the potential risks and/or additional health resource expenditure.  On the other 
hand, if we could easily identify patients with sustained and severe renal injury, and 
therefore a high probability of needing RRT, it may be prudent to consider starting RRT 
even at milder stages of AKI to provide renal support and in order to prevent, rather 
than correct, AKI-related complications [33].
Such biomarkers may be integrated into clinical decision algorithms that have previously 
relied only on conventional clinical parameters [33], enhancing further our ability to 
predict need for RRT.  A potential approach to future biomarker strategies for RRT is 
shown (Figure 1). For this, two cut-offs are needed, one that identifies a high likelihood 
of needing RRT, and another indicative that RRT is very unlikely. This is analogous to 
the approach currently taken with other biomarkers already in clinical use, such as 
BNP [39]. These cut-offs may be either absolute values, or an absolute or relative 
change from a baseline value.  The first cut-off would aid in the early identification 
of patients who have persistent and severe renal injury in whom rapid spontaneous 
recovery of renal function is improbable.  The second distinguishes those with milder 
tubular injury who are expected to experience prompt renal recovery.  These may also 
vary depending on the clinical setting, e.g. ICU vs cardiac surgery, etc.  For patients with 
values in the indeterminate range, the presence of  extenuating factors assist further in 
the decision for RRT.  Patients treated with conservative therapy should be monitored 
and reassessed, which may include repeated biomarker measurements.  Further studies 
are needed to first, establish appropriate thresholds, and second, to test this approach 
in prospective rigorous study.
Summary
A number of novel kidney injury specific biomarkers have recently been characterized 
that can be detected in the blood and urine.  Several of these biomarkers have 
shown value for the early detection and diagnosis of AKI, when benchmarked against 
conventional measures of loss of kidney function, such as sCr, urea or urine output. 
However, fewer data have evaluated the potential value of these biomarkers, either 
alone or integrated with additional clinical factors or traditional surrogate measures of 
kidney injury for early prediction of whether patients will develop severe AKI requiring 
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RRT. Selected studies, examining NGAL, cystatin-C, NAG, KIM-1, and α1-microglobulin, 
among others, have suggested these novel biomarkers have the potential to distinguish 
patients in whom RRT will be needed. This would imply that these biomarkers may be 
integrated into clinical decision algorithms, and could additively or even synergistically 
improve our current ability to predict need for RRT.  However, published studies have 
recognized limitations , which preclude our ability to adopt their findings into clinical 
practice today.  These include, but are not limited to, differences in patient populations 
(adult vs pediatric),clinical setting (cardiac surgery, nephrology consult, etc), type 
of  specimens (blood  vs urine), type of assays (standardized vs research platform-
based assays), small sample sizes, and lack of adjustment for relevant clinical factors 
in the analyses. Clearly more data are needed.  While currently available data are 
not sufficient to conclude that biomarkers should be used routinely for clinical decision 
making for RRT initiation today, additional data may significantly modify the clinical 
variability for initiation of RRT, and potentially translate into improved outcomes and 
cost-effectiveness.
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Abstract
Background and objectives
The decision to initiate renal replacement therapy (RRT) depends on several factors 
and is still ambiguous among clinicians. Patient related outcome however is negatively 
influenced by a cumulating fluid balance. In patients with oliguric AKI fluid balance 
control is an issue, especially when the decision to initiate RRT is postponed or even 
doubted by other factors.  It might therefore be helpful for clinicians to consult a 
prognostic model at ICU admission for risk assessment of need for RRT initiation within 
seven days of admission.  
Design, setting, participants and measurements
All consecutive admitted patients to an academic adult ICU between September 2007 
and April 2008 were included. The univariable predictive value of several predictors 
for the need of RRT was explored with logistic regression models. The additional 
predictive value of NGAL over these clinical predictors was calculated with multivariable 
logistic regression and expressed in increase in AUC (area under receiver operating 
characteristics curve). A prediction model was developed and its performance was 
quantified with respect to discrimination (AUC). The model was tested in an independent 
dataset, and a nomogram was developed. 
Results
Patients initiated on RRT within the first 24 hours of admission were excluded, leaving 
654 patients for the development of a prognostic model. Sepsis and MDRD eGFR 
at admission were the most important predictors for the need of RRT (Odds ratio’s 
respectively 7.3 en 0.96). Plasma NGAL did not have any additional predictive value on 
top of these (AUC=0.92 to 0.92).  
Conclusions
At the time of ICU admission the need for RRT within 7 days can be predicted accurately 
using the admission eGFR and a clinical diagnosis of sepsis by applying the presented 
prognostic model and nomogram.  
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Introduction
Acute kidney injury (AKI) is common among adult critically ill patients (30%) and about 
5% of the entire population is temporarily depending on renal replacement therapy 
(RRT) during their stay.  The mortality rate of patients requiring RRT in the Intensive 
Care Unit (ICU) is high (50%) with an accumulating fluid balance (FB) being associated 
with even worse outcome figures. In oliguric AKI the risk of daily fluid overload is high, 
especially when the decision to initiate RRT is postponed or doubted if clinicians decide 
to first challenge the kidneys’ urine production with high doses of diuretics. 
Several studies tried to address the issue of timing of RRT in relation to its effect on 
outcome such as mortality rates. However it seems difficult to interpret these data 
due to the wide variation in applied definitions of a timely initiation. Clearly observed 
evidence however is the association of a cumulating positive fluid balance with worsening 
outcome. Therefore it would perhaps be a challenge to investigate to effect of early 
fluid balance control on endpoints such as ventilator free days, ICU stay, and hospital 
stay and survival rates. In that context, an accurate prognostic scoring system for risk 
assessment for need for RRT within seven days of admission would be needed and 
helpful. 
Several studies describe the possible role for biomarkers for AKI, such as plasma NGAL, 
to participate in a predictive model for risk assessment for the need for RRT. With 
this study we tried to create an externally validate an easy to use prognostic clinical 
model and nomogram for risk assessment of initiation of RRT within seven days of ICU 
admission using two large cohorts of adult critically ill patients and to assess the additive 
role in this prediction for plasma NGAL.
Methods
Participants
The institutional review board of the Erasmus MC University Medical Center in Rotterdam, 
the Netherlands approved the study. All consecutive admitted patients to the general 
adult ICU (which treats general surgical, trauma, medical, neurological and neurosurgical 
patients, but not cardiac surgery patients) between September 2007 and April 2008 
were eligible for enrollment. Exclusion criteria included age under 18 years, refusal of 
consent, nephrectomy, chronic kidney disease (CKD stages 3, 4 and 5 based on eGFR 
criteria calculated with the baseline SCr values) and renal transplantation. Deferred 
consent was used, and written informed consent was obtained from all participants or 
their heath care proxy according to our deferred consent procedure [40].
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Data collection
Immediately following admission (T=0), blood samples were collected in EDTA tubes, 
processed and stored at -80°C. Serum creatinine (SCr) concentrations were measured 
at admission and thereafter daily at 6:00 am using the Roche enzymatic kit which 
is traceable to a reference method based on isotope dilution-mass spectrometry. 
Plasma NGAL was quantified with the Triage® point-of-care immunoassay [41]. The 
corresponding estimated glomerular filtration rate (eGFR) was calculated using the 
Modification of Diet in Renal Disease Study Equation (MDRD) [1].  Baseline SCr was 
defined as the patient’s steady state level within the four weeks prior to ICU admission. 
If this was not available, the admission value was used as the baseline SCr value. Other 
recorded variables included age, gender, body mass index (BMI), clinical diagnosis of 
sepsis, bicarbonate levels (HCO3
-), Urea, white blood cell count (WBC), Acute Physiology 
and Chronic Health Evaluation score (APACHE II), sequential organ failure assessment 
score (SOFA) and cumulative urine output (UP). The primary outcome variable was 
the need for RRT within seven days after ICU admission. AKI was classified as using 
AKIN criteria (Mehta) for increases in SCr only [42]. The diagnosis of sepsis was scored 
applying the international consensus criteria [43].
NGAL quantification
Plasma NGAL concentrations were measured using the Triage® NGAL Test point-of-care 
fluorescence immunoassay on a Triage MeterPlus (Biosite Inc, San Diego USA) using 
a commercially available NGAL cartridge. The devices used reported plasma NGAL 
concentrations between 46 and 1300 ng/ml. Urine NGAL levels were measured using a 
non-commercial Triage® immunoassay cartridge with a sandwich format immunoassay. 
Statistical analysis
Patients with plasma NGAL concentrations missing at admission were excluded; other 
missing data were statistically imputed using their expected values conditional on the 
observed NGAL levels, clinical parameters and the occurrence of AKI.  The univariable 
predictive value of NGAL for the occurrence of RRT was explored. The Area Under 
the receiver operating characteristic Curve (AUC) and its 95% confidence was used 
to assess the ability of the models to discriminate between RRT and no-RRT, and to 
quantify the difference between models with and without NGAL.  The 95% CI of AUC 
was calculated by a bootstrap resampling method. A prediction model was developed 
based on multivariable logistic regression. Internal validation was assessed using 
bootstrap resampling.  The model was fitted to an independent data from a single center 
prospective observational study of consecutive admitted adult ICU patients from Vicenza, 
Italy. Patients were enrolled between January and July 2007. This trial was originally 
designed as a prospective observational study evaluating consensus definitions for AKI 
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[44]. Patients with end stage renal disease on chronic RRT were excluded in the original 
study. Patients with CKD stages 3 or more were further excluded for the purpose of this 
study.  Only plasma NGAL was available in this study. To assess the applicability of the 
model to the independent dataset, we compared the regression coefficients between 
both datasets and tested for interactions between predictors and dataset. Finally, a 
scoring system was developed on the basis of regression coefficients in the multivariable 
model fitted on the combined datasets, including possible interactions, to obtain best 
estimates for both datasets and optimal precision. Statistical analyses were performed 
in R statistical software (R Foundation, Vienna, Austria).
Results
Descriptives
In total 663 patients were included in the study of which 558 had no-AKI at admission and 
654 did not receive RRT within the first 24 hours after admission.  Thus for developing 
the nomogram 654 participated in the analysis, their mean age was 56 years and 58% 
of this cohort was of male gender. Two hundred and two (30%) patients developed 
AKI and 66 (10%) were diagnosed with sepsis. The mean APACHE II and SOFA scores 
for the first 24 hours of admission were 19 (sd=7.5) and 6.2 (sd=3.8) respectively. 
At admission mean SCr concentrations were 90 (sd=68) μmol/L with a corresponding 
MDRD eGFR of 100 (sd=84) mL/min/1.73 m2. One hundred forty five patients (22%) 
died during the study (Table 1).
Neutrophil gelatinase associated Lipocalin
Plasma NGAL concentrations at admission were elevated in patients who were initiated 
on RRT compared to patients who were not. The relationship between NGAL and the 
probability of developing AKI was approximately linear. 
Prediction model
Based on the literature and previous work we identified sepsis, MDRD eGFR as 
established clinical predictors of severe AKI and RRT.  Both parameters were strong 
predictors of AKI or RRT in our data, and the additional predictive value of NGAL over 
these clinical predictors was limited. The AUC did not increase in the validation cohort 
when adding plasma NGAL to the model, and only 0.2 points in the external validation 
cohort (AUC 0.87 to 0.89).  Since the additional predictive value of NGAL was limited 
our final prediction model was based on the clinical predictors; sepsis (Odds ratio (OR) 
=5.0, p<0.01), MDRD eGFR (OR=0.96, p<0.01) measured at ICU admission (Table 
2.) The AUC of the model at T=0 was 0.92 and adding plasma NGAL did not add any 
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predictive value. The validation data set comprised 279 patients, of which 9 (3%) were 
initiated for RRT within 7 days after admission, which was very comparable to our own 
data. The baseline characteristics were highly comparable between the two datasets. 
The incidence of sepsis was comparable between both cohorts, the mean MDRD eGFR 
was lower in the validation data (83 versus 100 ml/min/1.73 m2) and mean urine 
production was higher (2541 versus 2113). In the validation set, only plasma NGAL at 
admission was available. Mean plasma NGAL was 187 (sd=246) in the total population, 
545 (sd=411) in patients who developed severe AKI and 151 (sd=187) in patients 
who did not, which was compatible with our data. With regard to the predictive value 
of NGAL, we confirmed our finding that although high NGAL is associated with a higher 
probability of developing severe AKI, the predictive value over clinical variables is limited. 
The prediction model performed well in validation set. Calibration was reasonable and 
discrimination was good (AUC admission model=0.87, AUC 24h model =0.75). 
Nomogram for RRT risk assessment
The final nomogram was developed on the combined development and validation 
data. The scores for individual patients can be calculated as shown in figure 1 and 
the corresponding predicted probabilities of RRT within 7 days after admission can be 
obtained (Figure 1).
Figure 1: Nomogram for risk assessment of initiation of RRT within 7 days of ICU admission in patients without 
AKI at admission.  MDRD eGFR: estimated glomerular filtration rate by the Modification of Diet in Renal Disease 
Study Equation measured at ICU admission; NGAL: neutrophil gelatinase associated lipocalin; AKI: acute kid-
ney injury; CRRT: continuous renal replacement therapy.
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162 Chapter 7
Discussion
The nomogram for risk assessment of RRT within 7 days of ICU admission at the time of 
ICU admission is an internally and externally validated predictive model that uses acute 
phase and easy-to-obtain clinical characteristics, which might be applied supporting 
the decision to start early RRT. On the basis of the MDRD eGFR value at admission and 
the clinical diagnosis of sepsis, the model accurately predicts the progression to need 
of RRT. This model provides a practical tool for physicians to identify individual patients 
with a high risk of severe AKI right at ICU admission. 
In four previous studies NGAL either measured in plasma or urine was consistently 
identified as a strong predictor for (severe) AKI in general adult critically ill patients 
[12, 41, 45, 46]. However, uncertainty still existed on the true additive value of NGAL 
for the prediction at the time of ICU admission, and accordingly the clinical applicability, 
on top of the conventional clinical characteristics routinely measured. The current study 
provides clarity on this matter and offers a model to predict outcome on the basis of 
an empirically weighted combination of predictors based on a large cohort with detailed 
and accurate information. The finding that NGAL levels do not add predictive value to 
clinical characteristics in the ICU setting was very robust, as shown by replication of 
the results in the different sensitivity analyses and in the independent data from Italy.  
Further improvement of predictive models would require the inclusion of additional 
variables, although it is unlikely that these variables would be clinical characteristics or 
currently available biomarkers.  Our analysis shows that the additional early contribution 
of NGAL measured in plasma is limited in the setting of admission to the adult Intensive 
Care.  Although several clinical studies in other patient cohorts such as pediatric and 
adult cardiopulmonary bypass patients have shown differently [5]. It is fair to say that, 
at least in our cohort, patients likely to develop severe AKI are admitted to the ICU 
already in an advanced stage of their illness. 
One conclusion from this study is that for an accurate prediction baseline eGFR values 
are not necessary. In the clinical practice of emergency medicine steady state baseline 
SCr and the corresponding estimated GFR are often not available which is required to 
assess AKIN scores. Furthermore, these scoring systems are developed as primarily 
retrospective tools for the purpose severity of disease scoring purposes. 
The nomogram developed here was based upon a distinct group of ICU patients, which 
might restrict clinical applicability. First, chronic kidney disease (CKD stage 3 or more) 
patients were excluded from the analysis. However, it is likely that those patients are 
easily identified at ICU admission due to the knowledge of patient chart history which 
will create a natural awareness of susceptibility for renal injury and progression of AKI 
on top of CKD.  Second, the model was based on adult patients only and it is therefore 
uncertain whether it is applicable for the identification of pediatric patients. Third, the 
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nomogram might only be directly applicable to patients treated in hospitals with high-
level of supportive and therapeutic care. And fourth, perhaps a further refinement of 
this proposed model is needed for example taking into account the gender differences 
in absolute SCr values. Unfortunately even this presented patient cohort was not large 
enough to perform a meaningful subset analysis. 
The nomogram was well applicable to the independent data set from Italy, although 
there were some differences between the development and validation data. Mean 
eGFR was lower in the validation data, probably due to the inclusion of some chronic 
renal patients in the validation cohort. Nevertheless the predictive effect of eGFR was 
similar in both data sets. Urine production was higher in the validation data and also the 
predictive effect of low urine production was smaller. We expect this to be due to the 
more prevalent administration in Italy, compared to the Netherlands. Diuretics artificially 
increase urine production and mask the high probability of AKI in these patients. The 
number of patients with sepsis was substantially higher in the validation data, and the 
predictive effect much smaller. We suspect that this is due to the differences in clinical 
setting (academic vs tertiary hospital). A limitation of the validation set is the limited 
number of patients (9) who were initiated on RRT after 24 hours of admission.  Future 
trials could now focus on new forms of treatment or early intervention such as the 
initiation of RRT for these very poor prognostic subgroups, especially if such treatments 
or interventions are potentially hazardous and patients with high chance of recovery 
should be excluded.
Conclusions
The nomogram for RRT risk assessment is an accurate and easy to use scoring system 
to be used at ICU admission. It is based upon clinical parameters readily available at ICU 
admission without the requirement of steady state baseline SCr values. Furthermore, 
although plasma NGAL is an accurate predictor for (severe) AKI at ICU admission its 
additional value over clinical predictors is limited. 
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Predicting recovery of renal function in patients with acute kidney injury (AKI) supported 
with renal replacement therapy (RRT) is one of the top ten questions in the field of 
current AKI research. However, defining renal recovery and accordingly the best time 
for discontinuation of RRT is difficult as reliable biomarkers are lacking.  
The Best Kidney study identified urine production (>500 ml/24 hrs) as the best 
predictor for successful discontinuation from RRT (AUC 0.81) in contrast to SCr (AUC 
0.64), however it’s predictive value is severely confounded by the use of diuretics [47]. 
Neutrophil Gelatinase associated Lipocalin (NGAL), a 25 kDa protein involved in iron 
transportation, is a potential tool for the determination of initiation of RRT [46, 48]. 
However, once a patient is initiated on RRT it remains to be elucidated how plasma NGAL 
concentrations will change. In order to determine plasma NGAL clearance and sieving 
coefficient (SQ) during CRRT, we measured pre-filter and effluent NGAL concentrations 
in three subjects after informed consent was obtained. Patients were hemofiltered with 
zero fluid balance, 2 liter post dilution mode in continuous veno-venous hemofiltration. 
Blood flow was set at 200 ml/min and regional citrate anticoagulation was used. The 
filters were ETO sterilized Aquamax HF 19 with an in vitro cut-off point of 55 kDa. NGAL 
levels were measured using a research based Enzyme-Linked Immunosorbent Assay 
with a detection limit of 10 to 4000 ng/ml. NGAL clearance per minute was estimated 
using the assumed stable plasma concentrations during CRRT over the first 12hrs and 
the calculated amount of NGAL present in the total effluent. SQ was calculated dividing 
the NGAL effluent concentration by the NGAL pre-filter plasma concentration. 
Three male anuric patients were studied (age 40-64 years). Their admission diagnoses 
were hemorrhagic shock, cardiopulmonary resuscitation and multitrauma. Baseline 
SCr values were 0.57, 0.66 and 0.68 mg/dL with SCr at time of CRRT initiation of 
3.7, 9.7 and 12.3 mg/dL. The estimated median plasma NGAL clearance (SD) was 4.8 
(1.89) ml/min with a median SQ (SD) of 0.147 (0.04). The pre-filter and effluent NGAL 
concentrations were plotted against time (Fig.1).
Normally, plasma NGAL is cleared through glomerular filtration and entirely processed 
by the proximal tubular cells [49]. However in case of AKI, plasma concentrations 
quickly rise even when eGFR is still normal and tend to quickly decrease when the 
injurious event subsides [5].Therefore, NGAL might have the potential to be an early 
indicator of renal recovery in critically ill patients supported by RRT. Our results suggest 
that plasma NGAL is hardly cleared during continuous veno-venous hemofiltration. A 
possible explanation lies in the fact that larger serum proteins effectively lower the 
passage of small proteins by forming a gel layer over the membrane pores. 
In conclusion, we have shown that CRRT does not substantially influence a patients’ 
plasma NGAL concentration and therefore doesn’t need to be taken into account when 
kinetics of plasma NGAL levels are used as an indicator for persistent renal injury or 
renal recovery in hemofiltered critically ill patients.
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Figure 1: Temporal patterns of the pre-filter plasma and effluent NGAL concentrations (ng/ml) in hours after 
initiation of continuous veno-venous renal replacement therapy in 3 individuals with anuric AKI.

Summary
170 Summary
Introduction
In this thesis we describe the role of biomarkers in the prediction and diagnosis of acute 
kidney injury in adult critically ill patients. The main goals were to provide an overview of 
the available literature, to study the predictive properties of biomarkers in a large cohort 
of adult critically ill patients and to rationalize the limitations for their applicability in 
clinical practice. The second part of this thesis discusses the applicability of biomarkers 
in clinical decision modelling for (early) initiation of renal replacement therapy. 
Overview of the literature
The first chapter describes the, at that time available, literature concerning the predictive 
value of several biomarkers for AKI in adult critically ill patients. The difference between 
early prediction and (late) diagnosis is emphasized. This is an evident issue since the 
inclusion of patients with an already risen SCr influences “predictive” test properties 
(John Kellum: There is no use in predicting rain when it is already raining). This is one of 
the explanations for the widely varying predictive test results of individual biomarkers. 
Biomarkers and AKI
Chapter two describes the most important study of this thesis based upon a prospectively 
enrolled cohort of 700 adult critically ill patients recruited from 1 September 2007 until 
1 April 2008. In all consecutively admitted patients blood and urine was sampled for 
biomarker measurements at 8 time points after ICU admission. Both plasma and urine 
Neutrophil gelatinase associated lipocalin concentrations were measured and tested for 
their predictive and diagnostic value for AKI. An important difficulty was the uncertain 
sample-time-to-injury relationship compared to a fixed model of cardiopulmonary 
bypass patients. Therefore the time-relationship between measurement and the 
predicted endpoint of AKI is important in the interpretation of the generated data. In 
this study the predictive value of biomarker concentrations measured at the time of 
ICU admission was evaluated. The results show that NGAL is just as good in predicting 
AKI as the functional marker eGFR, emphasizing however that patients with a slightly 
elevated SCr were not excluded for this analysis. NGAL concentrations in plasma and 
urine significantly increase when AKI is more severe classified by the RIFLE score. In 
patients with a seemingly normal eGFR at the time of ICU admission, NGAL‘s predictive 
performance is better compared to eGFR; even in a multivariable model with several 
clinical predictors for AKI. Approximately 60% of the patients who developed AKI 
during the first 7 days of their ICU stay already had a reduced eGFR at the time of ICU 
admission. Sepsis increases the levels of urine NGAL irrespective of the presence of AKI 
according to the RIFLE classification.  
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The definition for AKI has been a matter of debate for a long time now. The currently 
accepted international consensus definition is based upon a dichotomous outcome 
measure: The presence or absence of AKI based upon a rise in SCr compared to a 
“steady state” baseline value with an artificially chosen cut-off point of 50% rise in SCr. 
This assumption ignores the pathofysiological background of AKI which shows that the 
process of AKI is a gradual phenomenon wherein there is cumulative and progressive 
damage to the cells of the proximal and distal tubules. Although it is commonly accepted 
that SCr is not a sensitive measure of acute less serious tubular damage, there is at 
present no alternative.  It is therefore conceivable that under certain circumstances there 
might be a degree of tubular cellular damage resulting in excretion of hypersensitive 
biomarkers which is not yet reflected in an increase in SCr.  
In Chapter three is discussed whether plasma NGAL, urine NGAL and plasma and urine 
CyC are distinctive for transient and sustained kidney damage. Plasma NGAL appears to 
be increased for a short period of time in patients with transient AKI and is therefore in 
the early phases of AKI not very distinctive between both conditions in contrast to urine 
NGAL. The behaviour of plasma CyC is similar to that of SCr, which seems logical since 
both are functional markers instead of acute damage markers. Urine CyC is unfit for 
early distinction and displays a late expression in sustained AKI as well. 
Plasma and urine NGAL are, although there is some overlap in patients with pre-existing 
albuminuria, of different origin. Plasma NGAL originates from several different kinds of 
epithelial tissue (lung, intestine and kidney) and from specific granulae of neutrophils. 
Therefore there are concerns about the effect that a condition such as a systemic 
inflammatory response syndrome has on the diagnostic properties of plasma NGAL for 
AKI. Chapter four describes the effect of severe sepsis and septic shock on the diagnostic 
test properties of plasma NGAL for AKI. Evidently the production of plasma NGAL is 
increased indeed in patients with severe sepsis and septic shock compared to patients 
with other conditions, even irrespective of the presence of SCr based AKI. Despite the 
higher levels of plasma NGAL in these patients, it turns out that the diagnostic test 
properties for AKI remain to be similar. However, optimal cut-off values are higher in 
patients with sepsis and septic shock. Therefore, it is of outmost importance to realize 
that for the applicability of absolute biomarker concentrations in clinical decision models 
stratification for underlying disease state is justified (sepsis vs non-sepsis).
In Chapter five is tried to find an answer to the question why the reported predictive test 
property of biomarkers for AKI such as urine NGAL, KIM-1, pi- and alpha GST varies so 
widely and why they are so mutually different. In this study patients with an increased 
SCr at ICU admission and a diagnosis of sepsis where excluded. Furthermore, in order to 
study the biomarker expression pattern before the time of first rise in SCr time points were 
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recoded as such. NGAL turned out to be the most consistent marker which is expressed 
earlier compared to the other three biomarkers. The predictive performance of NGAL 
increased closer to the endpoint of (first) AKI. KIM-1 is a late marker discriminating for 
AKI only at the time of AKI. The expression of the constitutional enzymes pi and alpha 
GST is exhibited in a very short time frame.  Even at peak levels the predictive value 
for AKI is modest for both enzymes. Time and site of tubular injury should be taken into 
account for the interpretation of reported predictive test properties for AKI. This study 
demonstrates different expression patterns of biomarkers which might imply different 
fields of clinical utility. 
Biomarkers and RRT  
Chapter six provides an overview of the available literature which describes how 
biomarkers predict the need for renal replacement therapy (RRT). Worldwide, there 
is a wide variation in clinical practice when it comes to the time of RRT initiation. 
Several research groups have tried to study the effect of “early” initiation of RRT on 
hard outcomes such as mortality and ICU length of stay. However, without a single 
answer. Problematic in the interpretation of these data is that the applied definitions 
of early versus late are so diverse that the results of these studies are incomparable. 
This chapter explores the probable contribution of biomarker based decision models 
for prediction of initiation of RRT. The literature review shows that different biomarkers 
have the potential to perhaps contribute to the decision process. But at the same time, 
it must be recognized, supported in part by the results described in chapter four, that 
there are limitations in the in advance incorporation of cut-off values in these kind 
of clinical models. Actually, there is still too little literature available that can support 
that biomarkers should be routinely applied in clinical decision making for initiation or 
termination of invasive supportive therapy such as renal replacement therapy.   
With chapter six in mind, an effort was made to study in the available dataset which 
predictors are associated with the initiation of RRT. Chapter seven describes the results 
of this analysis and concludes that especially in septic patients the combination of this 
diagnosis and the available eGFR at the time of admission alone is the strongest predictor 
for the need for RRT. The clinical algorithm generated from the “Rotterdam cohort” has 
been validated in a similar cohort of adult critically ill patients in the San Bartolo Hospital 
in Vicenza, Italy resulting in similar results. By combining both datasets a nomogram 
could be developed, which might be a practical tool for clinical application. The additive 
contribution of plasma NGAL to this model is negligible. Therefore, it seems, at least in 
predicting the need for RRT in sepsis related AKI, there is no additive role for plasma 
NGAL.
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If the kidney is completely failing in critically ill patients this may, albeit imperfect 
compared to the healthy kidney, temporarily be replaced with a machine for renal 
replacement therapy. The principle of dialysis or hemofiltration depends on taking blood 
through a filter where waste, in the form of small molecules dissolved in the plasma, is 
washed out. These filters possess a certain pore size with the aim above all to remove 
small molecules but not larger substances such as proteins and red or white blood cells. 
Because creatinine travels easily through these filters it is often unclear, while being 
initiated on a RRT device, if recovery of renal function has occurred. Furthermore, urine 
production is often suppressed in the diseased kidney while being supported by RRT, 
due to the fact that when a patient is euvolemic there is simply not an evident excessive 
need to do so. Plasma NGAL is a small protein that accumulates in patients with acute 
renal failure. When a decreasing concentration of plasma NGAL might perhaps imply 
endogenous renal recovery this might be a potential predictor for successfully weaning 
off the extracorporeal support. However, at first it should be investigated if plasma is 
cleared (molecular seize 35 KDa) in patients still supported by RRT. Three case studies 
were performed and described in Chapter 8 in patients initiated on CRRT (CVVH) using 
a high cut-off filters (EFO Aquamax HF-19, in vitro cut-off point of 55 kDa). NGAL 
concentrations were measured before the hemofilter and in the effluent volume at 12 
time points after initiation of CVVH. The calculated clearance of plasma NGAL is 4.8 
ml-min. Thus there is some permeability, but the effective clearance is low so that 
potentially substantial decrease in plasma NGAL concentrations over a period of time 
might be tested as a predictor for renal recovery. And associated with that a potential 
tool for the decision to terminate CRRT successfully. 
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Inleiding
In dit proefschrift wordt de rol van biomarkers bij het voorspellen en diagnostiseren van 
acute nier schade bij volwassen kritisch zieke patiënten beschreven. De doelstellingen 
waren om een overzicht te geven van de beschikbare literatuur, de predictieve waarde 
te bestuderen in een grote populatie volwassen intensive care patiënten en om te 
rationaliseren wat de beperkingen zijn voor het gebruik in de klinische praktijk. Het 
tweede gedeelte van dit proefschrift behandelt de toepassing van biomarkers in een 
klinisch besliskundige model voor (vroege) initiatie van nierfunctievervangende therapie.
Literatuur overzicht
Het eerste Hoofdstuk beschrijft de op dat moment beschikbaar literatuur over de 
predictieve waarde van verschillende biomarkers voor acute nierschade bij volwassen 
intensive care patiënten. Daarin wordt benadrukt dat er een verschil bestaat tussen 
vroege predictie en (late) diagnose stelling. Dit is van belang omdat de inclusie van 
patiënten waarbij het SCr al is verhoogd de test eigenschappen beïnvloedt (John Kellum: 
There is no use in predicting rain when it is already raining). Dit is mede een verklaring 
voor de uiteenlopende test resultaten die gepubliceerd zijn. 
Biomarkers en AKI
In Hoofdstuk twee wordt de belangrijkste studie van dit proefschrift gepresenteerd 
die gebaseerd is op een cohort van 700 volwassen IC patiënten gerekruteerd van 1 
september 2007 tot 1 april 2008. Bij alle opeenvolgende opnames werd op een acht 
tal tijdspunten bloed en urine afgenomen voor biomarker bepalingen. Zowel plasma als 
urine neutrophil gelatinase associated lipocalin werden gemeten en beoordeeld naar 
hun voorspellende en diagnostische waarde voor acute nierschade. Een belangrijke 
moeilijkheid in dit cohort is dat er geen vastgesteld moment is waarop de nierschade 
begint zoals dat het geval is in cardiochirurgische patiënten. Daarom is de tijdsrelatie 
tussen de meetpunten en het te voorspellen eindpunt van belang voor de interpretatie 
van de gegevens. In deze studie is vooral gekeken naar de predictieve waarde van 
de concentratie direct bij binnenkomst op de IC. Hieruit blijkt dat NGAL even goed 
voorspellend is voor AKI als de klaringsmaat eGFR, aantekenend dat de mensen met 
reeds aanwijzingen voor nierschade niet geexcludeerd zijn. De concentraties van NGAL 
in plasma en urine nemen significant toe met de ernst van AKI gescoord volgens RIFLE. 
Bij patiënten met een normale eGFR bij IC opname voorspelt NGAL wel beter; zelfs in een 
multivariabel model met andere klinische parameters. Ongeveer 60% van de patiënten 
die AKI ontwikkelen op de IC hebben al een verminderde klaring bij IC opname. Sepsis 
induceert de excretie van NGAL in de urine onafhankelijk van de aanwezigheid van AKI 
volgens het RIFLE score systeem. 
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De definitie van AKI staat al langere tijd ter discussie. De huidige internationaal 
geaccepteerde consensus is die van een dichotome classificatie: Er is wel of geen AKI 
gebaseerd op een toename van serum creatinine ten op zichten van een “steady state” 
baseline waarde. Deze aanname gaat voorbij aan de pathosfysiologische achtergrond 
van AKI die leert dat het proces een geleidelijk fenomeen is waarbij er een cumulatieve 
en progressieve schade optreedt aan tubulus cellen. Hoewel het duidelijk is dat SCr 
geen gevoelige maat is voor acute minder ernstige schade is er op dit moment geen 
alternatief. Het is dan ook voorstelbaar dat er mate van schade is die zich (nog) niet uit 
in een toename van SCr maar wel in de productie en of excretie van hypersensitieve 
biomarkers. In Hoofdstuk drie is daarom gekeken of plasma en urine NGAL en Cystatine-C 
onderscheidend zijn voor lichte nierschade van voorbijgaande aard (Transient AKI) en 
aanhoudende nierschade (Sustained AKI) met een groter beschadigend effect. Plasma 
NGAL blijkt kortdurend verhoogd te zijn in patiënten met transient AKI en is daarom 
in de beginfase niet erg onderscheidend tussen beide. Dit in tegen stelling tot urine 
NGAL. Het gedrag van plasma Cystatine-C is vergelijkbaar met dat van SCr, wat logisch 
lijkt aangezien beide functionele biomarkers zijn in plaats van acute schade markers. 
Urine Cystatine-C is ongeschikt en is zelfs voor sustained AKI een biomarker die laat tot 
expressie komt. 
Voor plasma en urine NGAL geldt dat zij, hoewel er overlap is beschreven in patiënten met 
pre-existente albuminurie, van verschillende origine zijn. Omdat NGAL zich ook bevindt 
in andere epithelia zoals longweefsel en darmweefsel en in granulae van specifieke witte 
bloedcellen bestaat er zorg over het effect dat een systemic inflammatory response 
syndrome (SIRS) heeft op de diagnostische waarde van plasma NGAL voor AKI. Hoofdstuk 
vier beschrijft het effect van severe sepsis en septic shock op de test eigenschappen. 
Duidelijk naar voren komt dat er inderdaad meer plasma NGAL gegenereerd wordt bij 
severe sepsis en septic shock in vergelijking met patiënten met andere aandoeningen, 
zelfs bij de patiënten die volgens de SCr definitie geen AKI ontwikkelen. Ondanks deze 
verschillen blijkt de diagnostische waarde voor AKI gelijk te zijn in de groep patiënten 
met sepsis versus de groep patiënten zonder. Echter, de optimale cut-off waardes voor 
de diagnostische toets zijn hoger bij sepsis in vergelijking tot non-sepsis. Belangrijk om 
te realiseren is dan ook dat voor het gebruik van absolute concentraties van plasma 
NGAL voor klinische beslissingen er op zijn minst gestratificeerd zou moeten worden 
voor onderliggende ziekte (sepsis vs non-sepsis).
Met Hoofdstuk vijf wordt er voor verschillende urine biomarkers (NGAL, KIM-1, alpha- 
en pi-GST) gezocht naar een antwoord op de vraag waarom de predictieve waarde van 
deze markers in de literatuur zo uiteenloopt en onderling zo verschillend is. Daartoe 
zijn alle patiënten met een gestegen SCr bij opname geexcludeerd, evenals patiënten 
met sepsis. Er is een recodering toegepast om de expressie van de afzonderlijke 
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biomarkers inzichtelijk te maken voor het tijdspunt dat er voor het eerst een stijging 
van SCr detecteerbaar is. Van de ge-upreguleerde proteïnen is NGAL de vroegste en 
meest consistente biomarker. Waarbij de predictieve waarde beter wordt naar mate 
het meetpunt dichter bij het eindpunt komt. KIM-1 is een late marker die juist op 
het moment van eerste stijging van SCr het eerste discriminerende moment kent. De 
constitutionele enzymen vertonen een expressie in een zeer kort tijdsbestek. Zelfs op 
het punt van de hoogst gemeten concentraties is de predictieve waarde bescheiden. De 
tijd en plaats van tubulaire schade in relatie tot het meten van een biomarker in urine 
is dus van invloed op test eigenschappen. Het is voorstelbaar dat de met deze studie 
aangetoonde verschillende eigenschappen van de biomarkers een verschillend terrein 
van toepassing geïdentificeerd kan worden. 
Biomarkers en RRT
Hoofdstuk zes geeft een overzicht van de beschikbare literatuur die beschrijft hoe 
biomarkers voorspellen voor de noodzaak tot start van nierfunctievervangende therapie 
(RRT). Wereldwijd bestaat er een grote variatie in de klinische praktijk als het gaat om 
het moment van starten van RRT. Verschillende onderzoeksgroepen hebben getracht om 
het effect van vroeger of later starten van RRT te bestuderen op harde uitkomsten zoals 
mortaliteit of ICU ligduur, echter zonder een eenduidig antwoord. Want, problematisch 
bij de interpretatie van die data is dat de definities van vroeg of laat starten zo ver 
uiteenlopen dat de onderzoeksgegevens nauwelijks onderling te vergelijken zijn. 
Daarom wordt in dit hoofdstuk geëxploreerd wat de bijdrage van biomarkers voor AKI 
en of RRT zou kunnen zijn in een algoritme dat zou kunnen ondersteunen in de klinische 
besluitvorming voor RRT. Het literatuur overzicht laat zien dat verschillende biomarkers 
de potentie hebben om wellicht bij te dragen aan deze besluitvorming. Maar tegelijkertijd 
moet erkend worden, mede ondersteund door de resultaten beschreven in Hoofdstuk 
vier, dat er limitaties zijn bij het op voorhand incorporeren van cut-off waarden van 
biomarkers in dit soort modellen. Eigenlijk is er nog te weinig literatuur voorhanden 
die kan ondersteunen dat biomarkers routine matig moeten worden toegepast in de 
klinische besluitvorming voor het starten of stoppen van een invasieve ondersteunende 
therapie zoals nierfunctievervanging.
In het licht van de achtergronden uit Hoofdstuk zes is er gekeken in het NGAL cohort 
welke van de beschikbare predictoren geassocieerd zijn met het starten van RRT. 
Hoofdstuk zeven beschrijft de uitkomsten van deze analyse en concludeert dat vooral 
het hebben van sepsis in combinatie met de waarde van de estimated glomerular 
filtration rate (eGFR) bij ICU opname het meest predictief zijn voor de initiatie van RRT. 
Het klinische beslismodel dat gegenereerd is uit het NGAL cohort uit Rotterdam is in 
deze studie gevalideerd in een vergelijkbaar cohort van volwassen ICU patiënten in het 
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San Bortolo Hospital te Vicenza, Italië met als resultaat zeer vergelijkbare uitkomsten. 
Door beide cohorten te combineren is er een nomogram ontwikkeld, wat een praktische 
tool zou kunnen zijn voor klinische toepassing om op het moment van ICU opname 
een kans berekening te maken. De additieve bijdrage van plasma NGAL aan het model 
is verwaarloosbaar. Het lijkt er dus op dat in ieder geval bij het voorspellen van de 
noodzaak tot RRT in patiënten met sepsis gerelateerde AKI er geen rol is weggelegd 
voor plasma NGAL. 
Als er een volledige nierinsufficiëntie is opgetreden bij kritisch zieke patiënten kan dit, zij 
het kwalitatief veel minder goed dan een gezonde nier, tijdelijk vervangen worden met 
een machine voor nierfunctie vervangende therapie. Hiermee wordt bloed ontrokken uit 
de bloedbaan en door een filter geleid waar afvalstoffen, in de vorm van kleine in het 
bloed opgeloste moleculen, over worden uitgespoeld. Deze filters hebben een bepaalde 
porie grootte met als doel vooral kleine moleculen te verwijderen en stoffen zoals 
eiwitten niet uit te wassen. Tijdens een dergelijke behandeling is het vaak niet duidelijk 
of er herstel van nierfunctie is opgetreden, dit omdat de klassieke functionele parameter 
voor nierfunctie (Serum kreatinine) heel effectief door de machine wordt uitgewassen. 
Daarbij is ook de urine productie een moeizame maat voor herstel van nierfunctie omdat 
als de behandeling goed wordt uitgevoerd er voor de nier geen noodzaak is om urine 
te produceren. Plasma NGAL is een klein eiwit dat in verhoogde concentraties aanwezig 
is bij patiënten met een volledige nierinsufficiëntie. Om in de toekomst te kunnen 
bepalen of veranderingen in de plasma concentratie van de biomarker plasma NGAL 
een predictor zou kunnen zijn voor endogeen herstel van nierfunctie is er in Hoofdstuk 
acht bestudeerd of dit kleine eiwit (~35 kDa) geklaard wordt door de high-cut off filters 
(EFO Aquamax HF-19 met in vitro cut-off Point van 55 kDa) die worden toegepast 
in de kliniek. Concentraties zijn gemeten voor het filter en in het effluente volume, 
waaruit blijkt dat de klaring uitkomt op 4.8 ml/min. Er is dus enige doorlaatbaarheid, 
maar de effectieve klaring is zo laag bij deze porie grootte dat in potentie wezenlijke 
veranderingen in plasma NGAL concentraties een maat zouden kunnen zijn voor herstel 
van nierfunctie. 
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Tot slot
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‘Give light, and the darkness will disappear of itself.’
- Desiderius Erasmus 1466 – 1536 -
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